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ABSTRACT 
 
A RECOMBINANT CHOLERA TOXIN B SUBUNIT VARIANT (CTB-KDEL) 
EXHIBITS UNIQUE COLON MUCOSAL HEALING EFFECTS THAT HAVE 
THERAPEUTIC IMPLICATIONS FOR INFLAMMATORY BOWEL DISEASE 
Joshua M. Royal 
November 22, 2019 
 
This dissertation uncovers the mechanism and explores the utility of a 
recombinant cholera toxin B subunit (CTB) variant containing a KDEL endoplasmic 
reticulum (ER) retention motif (CTB-KDEL) as a drug candidate for the treatment of 
inflammatory bowel disease (IBD). CTB is a mucosal immunomodulatory protein that 
induces robust mucosal and systemic antibody responses. This well-known biological 
activity has been exploited in cholera prevention (as a component of Dukoral® vaccine) 
and vaccine development for decades. On the other hand, several studies have 
investigated CTB’s immunotherapeutic potential in the treatment of inflammatory 
diseases such as Crohn’s disease and asthma. Previously, we found that the plant-made 
variant of CTB (CTB-KDEL) could induce colon epithelial wound healing in mouse 
colitis models. Herein, Chapter 1 discusses the diverse therapeutic applications  of CTB 
and CTB variants. The methodology of the studies presented herein are described in 
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Chapter2.  Chapter 3 reveals CTB-KDEL induces colon epithelial wound healing 
in colitis via the activation of an unfolded protein response (UPR) in colon epithelial 
cells. CTB-KDEL’s capacity to induce a UPR and epithelial restitution/wound healing 
was corroborated in a dextran sodium sulfate (DSS)-induced acute colitis mouse model. 
Chapter 4 describes the feasibility of repeated oral administration of CTB-KDEL for the 
treatment of chronic colitis. This chapter addresses two key concerns with the 
development of CTB-KDEL for the treatment of IBD. First, can CTB-KDEL alleviate 
chronic inflammatory conditions of IBD, specifically in an ulcerative colitis model, and 
second, what are the consequences of CTB-KDEL induced immunogenicity on its 
efficacy. We found that weekly (QW) oral administration of CTB-KDEL dosed before or 
dosed after the onset of chronic conditions with QW and every three-day dosing (Q3D) 
could significantly reduce disease severity. The results indicate that the animals 
continued to respond to the medication over time and did not lose its efficacy with 
repeated dosing. Furthermore, the positive results in the delayed dosing group, mice 
dosed after the onset of chronic conditions, indicate that CTB-KDEL can alleviate 
chronic inflammation and reverse DSS-induced colonic damage.  The second part of 
Chapter 4 addresses the consequences of CTB-KDEL induced immunogenicity on its 
therapeutic effect. As CTB-KDEL is a derivative of the cholera vaccine antigen CTB, it 
is of critical importance to assess the consequences of an immune response to CTB-
KDEL. Pre-dosing mice with CTB-KDEL indeed elicited significant levels of anti-CTB-
KDEL IgA antibodies in the intestine before DSS exposure and throughout the rest of the 
study, however, those ADAs did not alter the therapeutic effect of CTB-KDEL against 
DSS colitis. Conversely, the immunogenicity of CTB could be beneficial for colitis 
treatment, since induction of IgA is associated with an anti-inflammatory response and 
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IgA plays an important role in maintaining mucosal homeostasis. Thus, we performed the 
same acute DSS colitis model using C3H mice since this strain cannot produce ADAs 
against CTB. Subsequently, we found that indeed CTB-KDEL could mitigate DSS colitis 
without inducing an antibody response. These results suggest that CTB-KDEL’s 
immunogenicity is not beneficial nor detrimental to its therapeutic effect. Lastly, in 
Chapter 5, we describe CTB-KDEL’s therapeutic effects on IBD patient colon explants. 
To simulate CTB-KDEL’s therapeutic potential in humans, its effects on epithelial repair 
responses and histological changes were evaluated in colon tissues obtained from IBD 
patients with various disease history and biological backgrounds. The results demonstrate 
CTB-KDEL’s efficacy in this translational model, as manifested by the induction of 
TGFB gene expression, upregulation of wound healing pathway genes and presence of 
viable crypts in the mucosa. Chapter 6 summarizes the effects of CTB-KDEL revealed in 
this dissertation and discusses future directions. 
In summary, CTB-KDEL exhibits unique colon mucosal would healing effects 
mediated by its colocalization to the ER and subsequent activation of IRE1/XBP1 
signaling in colon epithelial cells. Repeated oral administration of a CTB-KDEL 
effectively mitigates chronic DSS-colitis despite a robust immunogenic response. 
Additionally, CTB-KDEL induces wound healing responses in IBD patient colon tissues.   
These results presented herein provide implications for the unique therapeutic potential of 
CTB-KDEL that may address a significant unmet need in IBD treatment.
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CHAPTER 1: THERAPEUTIC POTENTIAL OF CHOLERA TOXIN B SUBUNIT FOR 
THE TREATMENT OF INFLAMMATORY DISEASES OF THE MUCOSA1 
 
 
1. Introduction 
UC is a class of inflammatory bowel diseases (IBD), along with Crohn’s disease 
(CD), that affects 286 per 100,000 persons (0.3% of total population) in the USA alone 
[1]. Although the etiology of UC remains elusive, genetic and environmental factors 
appear to trigger dysregulated mucosal immune responses, leading to the onset and 
progression of chronic inflammation, disrupted intestinal barrier function and epithelial 
damage in the colon [2]. There is no curative therapy available for UC; conventional 
treatment strategies aim to blunt the inflammatory response and establish remission using 
corticosteroids, aminosalicylates and immunosuppressive agents, but these agents have 
limited efficacy or severe adverse reactions, often requiring additional treatment or 
surgical resection of the colon and rectum [3]. The recent advent of anti-TNFα agents, 
however, has greatly improved the clinical outcome of IBD patients and revealed that 
mucosal healing provides an important endpoint in IBD treatment, as it is closely 
associated with sustained clinical remission, improved quality of life and fewer surgical 
operations and cancer incidence [4-9]. In a study evaluating 5-year treatment outcomes of 
 
1 Modified from: Toxins (Basel). 2017 Nov 23;9(12). pii: E379. doi: 10.3390/toxins9120379. 
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patients with newly diagnosed UC receiving corticosteroid therapy, the lack of mucosal 
healing was found to be the only factor associated with a more aggressive disease 
outcome requiring immunosuppression therapy, hospitalization or colectomy [10]. In two 
randomized, double-blind, placebo-controlled studies (ACT1 and 2), patients treated with 
the anti-TNFα infliximab who exhibited mucosal healing at week 8 showed a ~5-fold 
higher rate of clinical remission at week 30 than those without mucosal healing [11]. In a 
study of 513 Norwegian patients diagnosed with UC, mucosal healing was significantly 
associated with a low risk of future colectomy at a 5-year follow-up [12]. These clinical 
data have led to a general consensus that mucosal healing is the most important treatment 
goal in UC [13, 14]. However, a major problem is that current therapeutic options can 
achieve mucosal healing in only up to half of patients [15, 16]; in ACT1 trial, 45 – 47 % 
of those who received infliximab achieved mucosal healing, and similar results were 
observed in ACT2 trial [11]. Similarly, in a Phase III clinical trial of the anti-TNFα 
Adalimumab, 46.7% of patients who received the antibody showed mucosal healing [17]. 
The relatively low rates of mucosal healing is likely because the currently available UC 
drugs are, by and large, anti-inflammatory agents that do not specifically stimulate a 
tissue healing process. Mucosal healing is a complex and dynamic biological process 
involving spatial and temporal network of a number of mediators and cell types including 
epithelial, immune and stromal cells [5, 18]. Thus, mere inhibition of inflammatory 
responses does not necessarily facilitate mucosal healing. Development of a new drug 
specifically targeting mucosal healing will fill the gap in the current UC treatment 
paradigm.  
A clear definition of mucosal healing has yet to be determined [5, 18]. It has been 
inferred that mucosal healing involves the coordination of IECs, goblet cells, and Paneth 
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cells for healing of intestinal barrier function [5]. Additionally, intestinal epithelial 
wound repair is especially critical for mucosal healing in UC patients, because UC’s 
pathology is limited to the mucosa unlike CD that manifest as transmural disease [5], 
epithelial would healing has particularly significant therapeutic implications in UC [19]. 
Wound repair has been extensively studied in non-mucosal tissues such as the skin, but 
the same mechanism seems to be applicable to mucosae [18]; it involves three main 
overlapping phases, inflammation, proliferation and maturation. Each phase relies on the 
appropriate levels of cytokines and growth factors in the wound environment [20, 21]. 
Among these, TGFβ plays critical roles across all three healing phases; in the 
inflammation phase, TGFβ induces the recruitment of neutrophils and macrophages to 
“clean up” the wound environment and subsequently regulates immune cells to resolve 
inflammation. In the proliferation phase, TGFβ promotes angiogenesis, fibroblast 
proliferation and production of extracellular matrix (ECM) components, which leads to 
granulation tissue formation and wound contraction. In the maturation phase, TGFβ 
contributes to ECM remodeling by regulating the expression of various enzymes 
including matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) [5, 
18, 20-22]. Importantly, TGFβ can be a double-edged sword in mucosal remodeling; 
while TGFβ has beneficial effects during the early stage of wound healing, it can promote 
scar formation and fibrosis at the late stage [20, 23]. In addition, although TGFβ 
functions as a suppressor of epithelial cell tumorigenesis at an early stage of tumor 
development, its expression is correlated with tumor progression and poor prognosis at 
late stages [23]. Thus, a tight control of TGFβ signaling, when targeted to induce mucosal 
healing in UC, is critical, because UC poses an increased risk of developing colitis-
associated colorectal cancer (CAC) [24, 25]. Given that mucosal inflammation of IBD 
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reflects composite conditions including both nascent and established inflammations [26]. 
It is likely that TGFβ-mediated wound repair remains to play a significant role at least in 
some parts of UC colon mucosa.  
As discussed above, the development of a new drug specifically targeting mucosal 
healing could fill a gap in the current UC treatment paradigm. Unfortunately, there are no 
drugs specifically targeting mucosal healing currently available or in clinical 
development. Therefore, the goal of the studies presented herein is to uncover a first-in-
class therapeutic candidate for UC that can effectively treat intestinal damage and induce 
mucosal healing without suppressing systemic immune functions, a significant unmet 
need in current UC treatment paradigm.  This chapter describes the utility of a 
recombinant cholera toxin B subunit (CTB) variant as a drug candidate for the treatment 
of inflammatory diseases of the mucosa.  
 
1.1. Cholera Toxin  
Vibrio cholerae is a gram-negative bacterium that can colonize the 
gastrointestinal tract and cause life-threatening disease termed Cholera. Approximately 
2.9 million cases and 95,000 deaths occur each year around the world due to Vibrio 
cholerae infection. While the infection is often mild or without symptoms, 10% of 
infected persons will have severe disease that cause rapid loss of body fluids caused by 
profuse diarrhea and vomiting. If left untreated, death can occur within hours [27]. The 
principal virulence factor of V. cholerae is cholera toxin (CT), which consists of a 
catalytic A-subunit and a non-toxic homopentameric B-subunit (CTB) [28-30]. CTB 
binds cells through GM1 ganglioside receptors, which then mediates toxin entry into the 
cell. It has been previously shown that CTB can induce strong biological activities that 
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can enhance or suppress immune effects under normal and various immunopathological 
conditions without the toxicity associated with the CTA subunit [31]. Consequently, CTB 
has been widely studied as a mucosal immunomodulatory agent.  
In its most well-known immunostimulatory effects, CTB is used in the vaccine 
Dukoral®. Dukoral® is a WHO pre-qualified oral cholera vaccine, which contains heat-
killed whole cell V. cholerae and recombinant CTB (CTB; Table 1). Dukoral® stimulates 
the production of both antibacterial and antitoxin antibodies, including secretory 
immunoglobulin A (S-IgA) produced locally in the intestines [32]. CTB itself can induce 
potent mucosal and systemic antibody response upon mucosal administration in humans 
[33-35], which is largely due to the broad distribution of GM1 ganglioside on various cell 
types such as epithelial cells, macrophages, dendritic cells (DCs), B cells, T cells, and 
neurons [36-39]. Furthermore, the presence of GM1 ganglioside on the luminal surface of 
intestinal epithelial cells (IECs) and antigen presenting cells (APCs) in the gut seems to 
be essential for CTB’s strong mucosal immunostimulatory effects associated with MHC 
class II expression and local antigen enrichment [40].   Due to CTB’s strong mucosal 
immunomodulatory effects and the use of CTB in the vaccine Dukoral, the production of 
the protein in various recombinant production platforms has been widespread.  These 
include eukaryotes yeast cells to multicellular organisms such as plants and silkworms, as 
well as, prokaryotic cells such as genetically modified V. cholerae, E. coli, Bacillus and 
Lactobacillus (reviewed in [31]). In cell culture systems, recombinant CTB is produced in 
fermenters and bioreactors [31]. Alternatively, in plant expression systems, CTB is 
expressed in whole plants grown in controlled growth rooms or greenhouses. Previously, 
our lab has produced recombinant CTB in tobacco plants (Nicotiana benthamiana) using 
a plant virus vector overexpression system (CTB-KDEL; plant-made CTB; Table 1), with 
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the aim to economically mass-produce the vaccine antigen to facilitate global cholera 
vaccination [41-43]. CTB-KDEL was generated as a result of this endeavor; we 
genetically modified CTB to add an ER retention signal to the C-terminus, which was 
critical to mitigate ER stress/tissue necrosis upon overexpression and achieve high-level 
accumulation in leaf tissue [41, 42]. Our analyses demonstrated that CTB-KDEL is 
virtually identical to original CTB in regards to GM1-ganglioside binding affinity, 
molecular stability and vaccine efficacy to induce anti-toxin IgG and IgA antibodies upon 
oral immunization in mice [41]. Subsequently, we established a facile and scalable CTB-
KDEL production process, which allows us to obtain 400 mg of the purified protein from 
1 kg of leaf biomass (corresponding to 400 doses of Dukoral vaccine), with quality that 
can meet pharmaceutical standards [44]. 
 In addition to CTB’s immunostimulatory effects, CTB stimulates specific 
immunosuppressive effects against autoimmune disorders, excess inflammation, and 
allergic reactions [31, 45-49]. We have recently shown that oral administration of CTB-
KDEL mitigates colitis in chemically-induced acute and chronic colitis mouse models 
[50]. Although the underlying mechanisms are not well understood, recent studies have 
shed some light on these immunosuppressive effects induced by CTB. In this chapter, I 
summarize possible mechanisms behind CTB’s anti-inflammatory activity and discuss 
how the protein could impact mucosal inflammatory disease treatment. 
 
1.2. Cholera Toxin Structure and Mechanism in Gut Epithelial Cells 
To reveal the mechanism of CTB-induced biological activity, we must first 
understand the molecule. CT is classified as an AB5 toxin family, which includes the 
toxins of Shigella dysenteriae and enterohaemorrhagic Escherichia coli. The toxins are 
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usually composed of one A subunit and five B subunits (CTA and CTB, respectively, for 
CT). CTA consists of an enzymatically active 11-kDa N-terminal chain (CTA1) and a C-
terminal chain (CTA2) that connects CTA to the central pore of CTB. CTB has the 
capacity to translocate the CTA across the plasma membrane, mediated by the binding of 
GM1 ganglioside, and then escort CTA from the plasma membrane into the endoplasmic 
reticulum (ER) [51, 52]. The following summarizes CT’s retrograde trafficking 
mechanism. 
The five B-subunits form a central cylindrical pore lined by five amphipathic α-
helices that help form a highly stable homopentamer. The pentamer contains five GM1 
binding sites that lie on the outer edge of each B subunit [28, 53]. Due to an avidity effect 
from the pentavalent binding capacity, CTB has a very strong affinity (KD reported to be 
5 pM to 1 nM) to GM1, which is mainly localized in lipid rafts on the plasma membranes 
of many cell types [36-39]. Once CT is bound to GM1 (up to five gangliosides at once), it 
is endocytosed by clathrin-dependent and independent mechanisms and trafficked via 
retrograde transport from the Golgi to the ER [52]. It is also known that CT can undergo 
transcytosis across epithelial cells from the apical to the basolateral surface. However, 
regardless of how the toxin enters the cell, CT travels to the trans-Golgi network via early 
endosomal vesicles, independent of the late endosome pathway. The C-terminus of CTA2 
possesses a KDEL ER-retention signal for retrieval of CT from the cis-Golgi apparatus to 
the ER. Interestingly, the KDEL sequence is not vital for retrograde transport of CT to 
the ER. Mutations that alter the KDEL sequence on CT inhibit KDEL-dependent ER 
retrieval and decreased (albeit not completely) CT’s toxification [54]. Thus, it is thought 
that CT’s KDEL sequence—although not absolutely essential—improves the ER’s 
retrieval of the dissociated CT from the Golgi apparatus and prolongs the time of 
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retention within the ER [51, 54, 55]. Once in the ER, the CTA1-chain is dissociated from 
CTA2/CTB complex by protein disulfide isomerase (PDI). Subsequently, CTA1 enters 
the cytosol via the ER-associated degradation pathway and escapes proteasomal 
degradation [28, 51]. On the other hand, the fate (and remaining function, if any) of 
CTA2/CTB after releasing CTA1 in the ER is not well documented. Meanwhile, CTA1 
reaches the inner surface of the plasma membrane and catalyzes the ADP ribosylation of 
Gs, thereby continuously activating adenylate cyclase to produce cAMP. Increased 
intracellular cAMP impairs sodium uptake and increases chloride outflow, leading to 
water secretion and diarrhea [51, 56]. 
 
1.3. Mode of Action: CTB Directly Modulates Immune and Epithelial Cells  
Although the virulence mechanism and intracellular trafficking of CT has been 
well studied, the anti-inflammatory mechanisms of CTB are much less studied and 
understood. After a comprehensive literature review, it seems that there are at least two 
separate modes of action induced by CTB to modulate inflammatory responses: one that 
is based on immune cell regulation and another that is epithelial cell-mediated (Figure 1). 
In 1994, the immune suppressive effects of CTB were first reported by Sun et al. 
[57]. This report demonstrated that oral administration of mice with CTB conjugated with 
antigens (sheep red blood cells, horse red blood cells, and human γ-globulin) enhanced 
oral tolerance to the antigens, presumably through efficient presentation of antigens to 
immune cells in the gut-associated lymphoid tissue and the generation of regulatory cells. 
In a Commentary to this article, Weiner suggested that CTB could have enhanced 
tolerance by serving as a “selective mucosal adjuvant” and that this unique activity could 
be exploited to treat autoimmunity [58]. Subsequently, this seminal finding led to a new 
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field of studies in which CTB-antigen conjugates were applied to induce tolerogenic 
reactions to the conjugated antigens in various immunopathological conditions (i.e., 
encephalomyelitis, autoimmune diabetes, autoimmune arthritis, uveitis) and IgE-
mediated allergen hypersensitivity [45, 47-49, 59-69]. Through these studies, it became 
apparent there are two unique and distinct mechanisms of CTB responsible for the 
suppression of immunopathological reactions in allergy and autoimmune diseases: (1) to 
increase antigen uptake and presentation by different APCs through binding to their cell-
surface GM1 ganglioside receptors and (2) to induce anti-inflammatory and 
immunoregulatory activities by directly or indirectly acting on specific immune cells. The 
latter mechanism points to the possibility that CTB by itself may act as an 
immunotherapeutic agent; however, only a handful of groups have proven that CTB 
alone—without co-administration or conjugation of antigens—can induce an anti-
inflammatory response. Moreover, studies conducted with non-recombinant CTB 
(nrCTB, prepared by chemically dissociating CTA from CTB; Table 1) can have 
significantly skewed experimental results due to trace amounts of CT and CTA remaining 
in nrCTB samples preparations [31, 70, 71]. For example, we have shown that picomolar 
concentrations (<10 ng/mL) of CT significantly inhibited lipopolysaccharide (LPS)-
induced TNFα production in RAW264.7 cells, while recombinant CTB failed to induce 
such an effect at a concentration as high as 10 µg/mL [31]. Thus, the use of recombinant 
CTB is required to evaluate the effects unique to CTB. 
 
1.3.1. CTB Directly Impacts Immune Cells  
With regards to CTB’s immune cell regulation, Kim et al. demonstrated in murine 
spleen B cells that CTB dose-dependently increased IgA secretion and inhibited B cell 
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growth [72]. In the presence of IL-2, CTB significantly increased IgA isotype switching 
in LPS-activated B cells. These effects were reversed by the addition of an anti-TGFβ or 
soluble TGFβ1 receptor, which markedly inhibited CTB-stimulated IgA response. 
Further analysis in the same report revealed that CTB stimulated IgA2 B cells, 
upregulated TGFβ1 mRNA expression, and increased bioactive TGFβ1 levels, which is 
known to induce IgA isotype switching [72]. Thus, CTB stimulated a TGFβ-mediated 
IgA response that was dependent on IL-2 as a cofactor. These findings have contributed 
to our understandings of how CTB stimulates B cell IgA production, and potentially oral 
tolerance as well (see below). 
It is known that IgA antibodies help maintain mucosal homeostasis and play a 
role in immune protection [73, 74]. Thus, it seems possible that CTB administration 
could provide therapeutic effects in mucosal autoimmune disorders via IgA induction. 
For example, in an experimental mouse model of asthma, nrCTB suppressed the ability 
of DCs to prime for Th2 responses to inhaled allergen via an IgA-dependent manner [75]. 
In this study, co-administration of ovalbumin (OVA) and nrCTB suppressed classical 
features of asthma, including airway eosinophilia, Th2 cytokine synthesis, and bronchial 
hyperactivity in mice that were pre-sensitized with OVA-stimulated DCs in the lung. 
Furthermore, nrCTB treatment enhanced DCs’ potential to induce Treg cells in vitro; 
however, these Treg cells did not provide protection when transferred into the airways of 
naïve mice that received OVA challenge. In contrast, the transfer of B cells from 
OVA+CTB-DCs-immunized mice to OVA-sensitized naïve mice significantly reduced 
eosinophilia and lymphocytosis. It was also found that nrCTB caused a TGFβ-dependent 
increase in antigen-specific IgA in the airway luminal secretion, and this was attributed to 
nrCTB’s efficacy against the experimental asthma as the therapeutic effects were 
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abrogated in mice lacking luminal IgA transporter (polymeric Ig receptor), which is 
necessary for the transport of dimeric IgA across the epithelium into the luminal mucosa 
[76]. 
Meanwhile, IgA may not be the sole factor contributing to CTB’s ability to 
mitigate inflammatory diseases in the mucosa. For example, in the 2,4,6-trinitrobenzene 
sulfonic acid (TNBS)-induced mouse model of Crohn’s disease, daily oral administration 
over a four-day period of 100 µg CTB after the onset of TNBS-colitis immediately 
resolved weight loss and reduced inflammation [70]. In this case, the timing of mucosal 
restitution in regard to CTB administration did not likely result in IgA production. In a 
similar TNBS-colitis study, CTB administration reduced IL-12 and IFNγ secretion, 
inhibited STAT-4 and STAT-1 activation, and downregulated T-bet expression, 
indicating that CTB inhibited mucosal Th1 cell signaling [77]. Moreover, these results 
were confirmed in a small multicenter, open-label, and nonrandomized clinical trial in 
which 15 patients with active CD received three oral doses of 5 mg CTB per-week over 2 
weeks (six doses total) and were examined 2, 4, 6, and 10 weeks after the start of the 
study. Of the 12 patients who finished the study per protocol, seven responded to 
treatment and five were in remission by week six and maintained remission through week 
10 as defined by a CD activity index score ≤150 [78]. Of note, side effects seen in 33% of 
patients administered with CTB were mild (arthralgia, headache, and pruritus), and no 
safety concerns were raised throughout the trial [78]. 
Interestingly, CTB did not reduce disease severity in an oxazolone-induced colitis 
model performed by the same group [70]. Oxazolone-induced colitis is mediated by IL-4 
driven Th2 cells rather than IL-12/IFNγ-driven Th1 cells [70]. Thus, it appears that CTB 
administration had a specific effect on specific T cell functions involved in TNBS-colitis 
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[70]. Although the detailed mechanism by which CTB inhibited Th1 cell was not 
elucidated, it is possible that the binding of CTB to GM1 ganglioside on immune cells 
resulted in a signaling cascade of events that led to Th1 inhibition, because non-GM1 
binding CTB mutants do not modulate lymphocyte function [79]. In agreement with these 
findings, CTB decreased monocyte-derived DC maturation and IL-12 production upon 
LPS stimulation in vitro [80]. Moreover, CTB-pretreated, LPS-stimulated DCs induced 
low proliferating T cells that had enhanced production of IL-10 and reduced production 
of IFNγ. Rouquete-Jazdanian et al. showed that the binding of CTB to GM1 ganglioside 
directly prevented the activation and proliferation of CD4+ T cells [81]. This effect was 
induced by CTB-mediated sphingomyelinase activation that subsequently increased the 
production of ceramides, which are known cell cycle arrest inducers [82]. CTB also 
inhibited protein kinase Cα, a pro-growth cellular regulator, which was linked to CTB-
induced lipid raft modifications and ceramide-mediated inactivation [83, 84]. 
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Figure 1. Summary of mechanisms involved in cholera toxin homopentameric B-subunit 
(CTB)’s inflammatory disease intervention. 
 
1.3.2. A Plant-Made CTB variant (CTB-KDEL) Directly Modulates Epithelial Cells 
Besides serving as a barrier lining the mucosal surface, epithelial cells have 
multiple functions associated with the maintenance of gut homeostasis and mucosal 
healing, and crosstalk between epithelial and immune cells is an important component of 
those complex biological processes [85, 86]. Even though CTB first encounters epithelial 
cells in the gut, the CTB-mediated modulation of epithelial cells and its consequence to 
the mucosal immune system have largely been ignored in comparison to the protein’s 
direct impacts on immune cells. 
In one small study, CTB was shown to induce a dose-dependent increase of IL-10 
mRNA levels in the colon epithelial cell-line T84 [87], hinting that CTB could induce 
epithelial cell-mediated immune modulation [88]. We have recently characterized CTB’s 
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global impacts on the gut to further our understanding of its unique biological activities. 
Using CTB-KDEL [42, 89], we have shown that oral administration of the CTB variant 
significantly altered several immune cell populations in the colon lamina propria [50]. 
Two-weeks after two oral 30 µg CTB-KDEL administrations, Th2 and Treg cells 
increased in the colon lamina propria. This is not the first report of CTB-induced increase 
in these cell types [46, 67, 69, 90, 91]. For instance, it has been shown that oral 
administration of a CTB–insulin conjugate in NOD mice induced a shift from Th1 to Th2 
profile while generating Treg cells [46]. Additionally, intraperitoneal administration of 
nrCTB to rats increased Treg cells in the peripheral blood 24–72 h after ischemia [90]. 
Besides the specific T helper cell subsets, our study has also revealed that innate immune 
cells—including dendritic cells, natural killer cells and macrophages (both M1 and 
M2)—populations were increased in the colon lamina propria two weeks after CTB-
KDEL oral administration [50]. Furthermore, a global gene expression analysis revealed 
that CTB-KDEL had more pronounced impacts on the colon than the small intestine, with 
significant activation of TGFβ-mediated pathways in the colon mucosa [50]. Given that 
there is a strong link between epithelial-derived TGFβ and innate immune cells in wound 
healing [92-94], the results provided implications for the potential utility of CTB-KDEL 
to promote colonic mucosal health. Subsequently, we found that CTB-KDEL induced 
TGFβ-mediated wound healing in Caco2 colon epithelial cells. Furthermore, oral 
administration of CTB-KDEL in mice protected against colon mucosal damage in acute 
colitis induced by dextran sodium sulfate (DSS). Two oral doses of as low as 1 µg of 
CTB-KDEL mitigated clinical signs of disease (body weight loss, decreased 
histopathological scores, and blunted escalation of inflammatory cytokine levels) and 
upregulated wound healing-related genes [50]. Interestingly, CTB-KDEL administration 
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prevented fibrosis associated with acute colitis in mice; hence, the protein did not appear 
to overstimulate TGFβ signaling, at least under the conditions employed in the study. In 
fact, TGFβ gene expression levels were high during the early inflammatory phase and 
became lower in the recovery phase of the acute colitis model in CTB-KDEL-treated 
mice. 
The main driver of intestinal inflammation in the DSS-colitis model is the damage 
to the epithelial barrier lining the colon that allows intestinal microbiota into submucosal 
compartments, in contrast to TNBS-induced colitis [95-99], and meanwhile the 
therapeutic effects were observed immediately upon CTB-KDEL administration. 
Therefore, we concluded that CTB-KDEL’s protective efficacy in the DSS colitis models 
were attained by the induction of TGFβ-mediated colonic epithelial wound healing. 
Given that chronic inflammation and injury of the bowel, such as inflammatory bowel 
disease (IBD), pose an increased risk of developing colitis-associated colorectal cancer 
(CAC) [24, 25, 100, 101], CTB-KDEL’s effects were also examined in the azoxymethane 
(AOM)/DSS mouse model of CAC. Biweekly oral administration of CTB-KDEL over 9 
weeks significantly reduced inflammation and tumorigenesis in this model, highlighting 
its therapeutic potential in intestinal injury and inflammatory bowel disease, such as 
ulcerative colitis (UC) [50]. Therefore, the finding that CTB-KDEL is a topical agent that 
facilitates TGFβ-based mucosal wound healing in UC and CAC mouse, supports a 
hypothesis that CTB-KDEL could help address important issues pertinent to therapeutic 
strategies for mucosal healing in UC. 
It is of importance to point out that many of the effects observed in the 
aforementioned studies using CTB-KDEL may be unique to the plant-made variant, as it 
has a mutation at amino acid position 4 and an ER retention signal sequence at the C-
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terminus (N4S-CTB-SEKDEL; [89]). The ER-retention sequence was added to CTB-
KDEL to improve production in planta, while Asn4→Ser mutation was introduced to 
avoid N-glycosylation [42, 89]. The addition of the KDEL sequence to N4S-CTB 
significantly reduced ER stress that otherwise caused poor production yield. It is thought 
that the KDEL sequence helped prolong CTB-KDEL’s residence time in the ER to allow 
for proper folding and assembly. 
The protein ER retention mechanism involving the KDEL receptor is highly 
conserved among eukaryotic organisms [102]. Thus, there is a possibility that the artificial 
KDEL sequence of CTB-KDEL may prolong the protein’s residence in the epithelial 
cells upon binding to cell-surface GM1 ganglioside and retrograde transport into the ER, 
as has been demonstrated for CT [52, 54].  
Regardless of whether the ER retention signal had a significant contribution to the 
mucosal healing activity in the mouse colitis models, the study has provided evidence 
that CTB can exhibit a therapeutic effect against colitis in an epithelia-dependent manner, 
warranting further investigation of CTB’s impacts on epithelial cells. 
 The overall goal of this project is to develop CTB-KDEL as a biotherapeutic to 
facilitate mucosal healing in UC patients. To that extent, the objective of this dissertation 
is to investigate how CTB-KDEL’s C-terminal KDEL sequence contributes to the 
protein’s mucosal healing activity in vivo, in vitro, and ex vivo.  To achieve this goal I 
formed three specific aims. First, I aimed to determine if the CTB-KDEL-mediated 
reduction of colitis we previously reported was unique to the KDEL-tagged protein in a 
mouse model of DSS-colitis [50], while  investigating if CTB-KDEL’s epithelial healing 
activity, intracellular retention, and signaling pathways were affected by the protein’s 
KDEL sequence using a series of CTB-KDEL and CTB analogues. Second, I determined 
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if the immunogenicity of CTB-KDEL impacts its immunotherapeutic efficacy and to 
determine the efficacy of CTB-KDEL in a mouse chronic colitis model. Lastly, I aimed 
to determine if CTB-KDEL’s KDEL sequence contributes to the protein’s translational 
efficacy using a UC patient colon tissue explant.    
  Collectively, the research in this dissertation characterized CTB-KDEL’s colon 
mucosal healing efficacy, mechanisms, and translatability at cellular and molecular 
levels, supporting the development of CTB-KDEL as a new topical UC drug. 
Furthermore, this dissertation discloses previously undescribed impacts of CTB and its 
derivatives on colon epithelial cells, providing new information to the fields of mucosal 
immunology and pathophysiology. 
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CHAPTER 2: MATERIALS AND METHODS2 
 
 
CTB variants. Table 1 summarizes CTB variants used in the present study. CTB-KDEL 
and the non-GM1-binding mutant G33D-CTB-KDEL [50] were produced in N. 
benthamiana and purified to > 95% homogeneity with an endotoxin level of < 1 
endotoxin units per mg, essentially as described previously [44, 89] but with modification 
in the final chromatography step to selectively purify the proteins with fully intact C-
terminus (manuscript in preparation). CTB, CTB-KDE and eCTB-KDEL were produced 
in E. coli BL21(DE3) according to Hamorsky & Matoba [103], and purified to > 95% 
homogeneity with an endotoxin level of 0.05 -0.1 endotoxin units per mg. Purity and 
pentamer formation were assessed by SDS-PAGE under denaturing and non-denaturing 
conditions, whereas the molecular weight of each CTB variant was verified by mass 
spectrometry, as described before [89]. 
 
 
2 Animals: Eight-week-old C57BL/6J, C3H/HeJ, or Rag1-/-  female mice were obtained 
from Jackson laboratories (Bar Harbor, ME). Animal studies were approved by the 
University of Louisville’s Institutional Animal Care and Use Committee. 
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Caco2 wound healing assay. The Caco2 wound healing assay was performed as 
previously described [50].  Briefly, the cells were seeded and grown in complete growth 
medium (EMEM + 20% FBS, 1x penicillin-streptomycin) to confluence in 6 well plates 
 (Thermo Scientific Nunc Cell-Culture Treated, Roskilde, Denmark). Afterward, the 
culture medium was discarded, cells were washed with PBS and then incubated in serum-
free media for 6 hours. The cell monolayer was then scratched with a 200 µL sterile 
beveled pipette tip to generate two 0.5–1.0 mm across linear “wounds” per well and 
washed with PBS. A test compound (CTB, CTB-KDEL, CTB-KDE or eCTB-KDEL at 
0.1-10 µM), a positive control (0.2 nM [i.e. 5ng/mL] recombinant TGFβ1; Abcam, 
Cambridge, MA), a vehicle control (PBS) and/or 4µ8C (0.5 µM; MilliporeSigma, 
Burlington, MA) were subsequently added in fresh serum-deprived medium. 
Photomicrographs of the wounds were taken 0, 24, and 48 h after the wounding at 4X 
magnification. Quantification of the remaining cell-free area to the initial wound area was 
measured using the public domain software Image J (http://rsbweb.nih.gov), and 
calculated as a mean percentage (n = 2 experimental replicates) per well. The culture 
medium/supernatants were collected from each well 24 or 48 h after wounding and stored 
at -80 °C until analysis. The culture supernatants were analyzed by a human 
Cytokine/Chemokine or TGFb1, 2, 3 Magnetic Bead Panel (EMD Millipore, St. Charles, 
MO). The panel was analyzed with a Milliplex MAP Kit on a MagPix with Luminex 
xMAP technology. Each experiment was performed with 4 biological replicates per 
construct (n = 4). 
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Flow cytometry. Flow cytometry was used to assess the binding of CTB and CTB-
KDEL molecules to Caco2 cells, according to a well-established procedure. Briefly, 1 
×105 cells were seeded in EMEM (serum free) in the presence of 1 µM CTB or CTB-
KDEL and incubated for 15 minutes on ice. Next, cells were washed and blocked with 
3% BSA (Sigma) on ice. Then cells were incubated with the rat anti-CTB monoclonal 
antibody 9F9C7 (1.75µg/mL), which was produced in-house from a rat hybridoma cell 
line, for 1 h at room temperature and washed before incubation with a rabbit Alexa 
FluorTM 488 anti-rat IgG (H+L) (A21210, Life Technologies, Eugen, OR) for 1 h on ice. 
Finally, cells were washed and analyzed with a FACSCalibur (Becton Dickinson), 
counting 10,000 cells per sample. Data were acquired BD FACSCanto II and analyzed 
with FLOWJO v10 data analysis software, using PBS as a negative control (n = 4).  
 
Caco2 cell immunofluorescence. Cells were seeded 2 x 105 cells/well in Lab-Tek II 
chamber slides (Thermo, Rochester, NY) and grown for 72 h in complete growth 
medium. The media was subsequently removed, and cells were washed with PBS 
followed by a test compound (CTB or CTB-KDEL at 1µM) or a vehicle control treatment 
in fresh serum-deprived medium. Cells were incubated for 24 h at 37°C in a humidified 
5% CO2 then fix, permeabilized, and stained. Briefly, after treatment cells were washed 
with PBS, they were fixed in 0.4 mL 4% paraformaldehyde in PBS for 15 min at room 
temperature. Then cells were permeabilized with 0.4 mL 0.2% TitonX-100 in PBS for an 
additional 15 min at room temperature. Subsequently, cells were blocked (3% BSA, 
Sigma) and treated with 4.4 µg/mL of the anti-CTB monoclonal antibody 9F9C7 and 1 
µg/mL of rabbit anti-KDEL receptor pan pAb (Thermo PA5-67422) for 3 h at room 
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temperature. After subsequent washing (PBS), an anti-Rat IgG (H+L) Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 488 (Thermo) and anti-Rabbit preadsorbed IgG H&L 
(Alexa Fluor® 555) was applied to cells for 3 h at room temperature followed by 
additional washing with PBS. Cells were then mounted with coverslips using mounting 
medium for fluorescence with DAPI (VECTASHIELD®, Burlingame, CA). The 
proximity ligation assay (Duolink® PLA, Sigma) was performed according to the 
manufacturer’s protocol using the same fixation/permeabilization and primary antibody 
application protocol as described above using 1 µg/mL of rabbit anti-KDEL receptor pan 
pAb (Thermo PA5-67422) and 1:200 goat anti-CTB pAb (Emdmillipore). Slides were 
analyzed by wide-field fluorescence confocal microscope (60x magnification, Z-stacked 
images). Co-localization statistical analysis was performed using Imaris software 
(Bitplane), values were calculated in PLA signals per cell. 
 
Co-immunoprecipitation. Caco2 cells (1 x 106) were seeded in 10 cm2 plate and 
incubated in EMEM with 20% of FBS for 48 hours. After changing the medium to 
EMEM without FBS supplement, 1 µM of G33D-CTB-KDEL, CTB or CTB-KDEL, or a 
vehicle control (PBS) were added to the cells and incubated for 24 h. Cells were washed 
with PBS and cell lysates were prepared in 500 µL of T-PER buffer (Thermo fisher 
scientific) supplied with 1x protease, phosphatase inhibitor (Thermo fisher scientific). 
After centrifugation at 13,000 g for 10 minutes, supernatants were mixed with 4 µg of an 
anti-CTB antibody (7A12B3, which was produced in-house from a rat hybridoma cell 
line) or anti-BiP antibody (Cell Signaling Technology, Danvers, MA) or an anti-IRE1α 
antibody (Cell Signaling Technology). After incubation at 4 ℃ for 24 h, 10 µL of Protein 
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A beads (Santa Cruz Biotechnology; Dallas, TX) were added. After additional incubation 
at 4 ℃ for 2 h, the mixture was washed with T-PER buffer. The immunoprecipitated 
proteins were detected by an immunoblot analysis using 1 µg/ mL of the rat anti-CTB 
antibody 7A12B3 (produced in-house), 2 µg/mL of an anti-KDEL receptor (KDELR) 
antiserum (Abcam), 2 µg/ ml of an anti-BiP antibody (Cell Signaling Technology) or 2 
µg/mL of an anti-IRE1α antibody (Cell Signaling Technology).  
 
XBP knockdown with siRNA.  In a 6-well tissue culture plate, 2 x 105 Caco2 cells were 
seeded per well in 2 ml of EMEM with 20% FBS and 1x penicillin-streptomycin. Small 
interfering RNA (siRNA) was used to silence XBP1. The human XBP1 siRNA and 
scrambled sequences siRNA (control) were purchased from Santa Cruz Biotechnology. 
When cells were 60–80% confluent, 1 µg of siRNAs was transfected by lipofectamine 
transfection reagents (Santa Cruz Biotechnology). Subsequently, the wound healing assay 
was performed as described above, and total RNA was isolated by RNeasy Microarray 
Tissue Kit from Qiagen to verify XBP1 levels using the XBP-1 (h) primer set supplied 
from Santa Cruz Biotechnology. 
 
Immunoblot analysis. When Caco2 cells were 60–80% confluent in EMEM 
supplemented with 20% FBS and 1x penicillin-streptomycin, the medium was changed to 
EMEM without FBS supplement and treated 1 µM of G33D-CTB-KDEL, CTB or CTB-
KDEL, or a PBS vehicle control. After 24 h incubation, cell lysates were prepared with 
T-PER buffer supplied with 1x protease, phosphatase inhibitor (Thermo Fisher 
Scientific). Cell debris were removed by centrifugation at 13,000 g for 10 min at 4℃. 
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One hundred µg of total proteins were loaded for SDS-PAGE analysis, using a 10 % of 
Bolt Bis-Tris Plus gel (Thermo Fisher Scientific) to separate large-size phosphorylated 
proteins in MES-based running buffer. To analyze the intracellular stability of CTB and 
CTB-KDEL, Caco2 cells were incubated 4 h with 2 µM of CTB or CTB-KDEL, washed 
and immediately analyzed or incubated in EMEM for additional 12 or 24 h before 
analysis by immunoblot using 1.75 µg/mL of the rat anti-CTB monoclonal antibody 
7A12B3. To detect UPR markers, we used 2 µg/mL of an anti-BiP antibody (Cell 
Signaling Technology), an anti-IRE1α antibody (Cell Signaling Technology) or an anti-
PERK antibody (Cell Signaling Technology). Loading control was β-actin, which was 
detected by 1 µg/ mL of an anti-β-actin antibody (Santa Cruz Biotechnology). For mouse 
primary colon epithelial cells, cells were isolated from 3 - 6 cm of the colon from four 
mice. Colons were cut open lengthwise, washed, and then cut into 2 mm pieces. The 
tissues were washed 20 times in cold PBS followed by a 20 min incubation at room 
temperature in 50 mL conical tubes containing 30 ml of pre-warmed CMF HBSS/0.1% 
FBS and 2mM EDTA on a rocking platform at 20 rmp. The tissues were allowed to settle 
by gravity for 30 seconds and then the supernatant was discarded. To separate epithelial 
cells, the tissues were resuspended in 10 mL cold (4°C) CMF HBSS/1.5% FBS and 
pipetted up and down three times viciously. The intestinal pieces were allowed to settle 
and then the supernatant was filtered through a 70 μm filter. This cell separation step 
followed by filtration was repeated 3 times creating four fractions of filtered 
supernatants. Fractions 3 and 4 were combined and centrifuged at 300 x g for five 
minutes at 4°C. Supernatants were carefully discarded and the pellet was resuspended in 
10 mL cold (4°C) EMEM with 20% FBS followed by a subsequent 200 x g 
centrifugation. Finally the cells were resuspended in EMEM with 20% FBS, counted, and 
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plated. Thereafter, the mouse primary colon epithelial cells were subjected to the same 
immunoblot analysis protocol as mentioned above for Caco2 cells.    
 
The DSS-induced acute colitis study. For the acute DSS recovery model of intestinal 
injury, 10 mice per group, randomly assigned, were used. DSS exposure was initiated on 
the day mice turned 9 weeks old (day 0), using a modified method [50]. Body weights 
were measured at the initiation of DSS exposure as a baseline and every morning 
thereafter to determine percent change. Animals received 3% DSS (M.W. 36,000 to 
50,000; MP Biomedicals, Santa Ana, CA) in drinking water for 7 days. On the 7th day of 
DSS exposure, animals gavaged with PBS, CTB or CTB-KDEL after sodium bicarbonate 
administration, as described previously [89], and allowed to recover 7 days during which 
the animals received normal drinking water.  
 
Histology. Colons were removed and washed with PBS. A portion of the distal colon was 
fixed with paraformaldehyde overnight and stored in 70% ethanol until paraffin 
embedding, sectioning and routine H&E staining. Inflammation scoring was performed 
as previously described [50]. Tissue sections from 10 mice were scored in a blinded 
manner and averaged for each group.  
 
Immunohistochemistry (IHC). Colons were removed and washed with PBS (n = 10). A 
portion of the distal colon was fixed with paraformaldehyde overnight and stored in 70% 
ethanol until paraffin embedding and sectioning. Sections were deparaffinized with 
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Citrisolv and rehydrated through several ethanol washing steps ending with incubation in 
distilled water. Antigen retrieval was performed overnight with a 2100 Retriever 
(Electron Microscopy Sciences) using a pH 6.0 buffer. Tissue sections were blocked for 
endogenous peroxidase, avidin, biotin, and serum from the animal in which the secondary 
antibody was raised. Primary antibody (anti-E-cadherin 1:100; Abcam) was incubated 
with the tissue sections for 1 h at room temperature. The Vectastain Elite ABC kit (goat 
anti-rabbit; Vector Labs, Burlingame, CA) was used to label the primary antibody. E-
cadherin+ cells were visualized with the ImmPACT DAB Substrate Kit (Vector Labs) 
and then dehydrated through an ethanol gradient and finally incubated with Citrisolv. 
Sections were scanned using an Aperio ScanScope CS (Leica Biosystems, Buffalo 
Grove, IL).  
 
RNA isolation. Distal colon tissue (~14 mg) from each animal, initially stored in 
RNAlater (Qiagen, Valencia, CA) at -20 °C, was placed in QIAzol lysis reagent and 
homogenized. An RNeasy Microarray Tissue Kit from Qiagen was used to purify the 
RNA from the tissue homogenate. RNA concentration, quality and purity were confirmed 
by spectrophotometer then stored at -80°C until use. 
 
qRT-PCR. First strand cDNA was obtained from reverse transcription of 100 ng RNA 
using a SUPERSCRIPT VILO cDNA synthesis kit (Life Technologies, Carlsbad, CA) 
according to the manufacturer’s instructions. Template cDNA were added to a reaction 
mixture containing RT² SYBR Green Master Mix (Qiagen) and loaded in RT² Profiler 
PCR Array Standard 96 well Plates (Qiagen). These plates contain pre-spotted individual 
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gene expression probes for the detection of genes of interest as well as the house keeping 
genes 18S, ACTB and GAPDH. Gene quantification was carried out on a 7500 Fast Real-
Time PCR System (Applied Biosystems) with the following conditions: 1 cycle (10 min 
at 95 °C); 40 cycles (15 s at 95 °C; 1 min at 60 °C). The 7500 Software v2.0.6 (Applied 
Biosystems) was used to determine the cycle threshold (Ct) for each reaction and derive 
the expression ratios relative to control. Wound healing pathway analysis was performed 
with a RT2 Profiler PCR Mouse Wound Healing Array (Qiagen, Manchester, UK) under 
the same conditions described above. 
 
Treatment and culturing of colon explants obtained from ulcerative colitis patients. 
All research involving human tissue was performed in accordance with relevant 
guidelines and regulations established by the University of Louisville Institutional 
Review Board Committee. The treatment and culturing of colon explants was performed 
using an immersion culturing system developed from a previously-described methods 
[77, 104, 105]. Colorectal tissues were obtained from consenting patients at the time of 
colectomy. Immediately after excision, colectomy tissue was placed in complete medium 
(RPMI 1640 supplemented with 2 mM L-glutamine, 10 mM HEPES buffer, 10 μg/mL 
gentamicin, 100 U/mL each of penicillin and streptomycin, and 10% FBS (Hy-Clone)) on 
ice and transported to the lab. The tissue was immediately divided and placed in organ 
culture dishes at 37°C in a humidified 5% CO2. The tissues were placed luminal side up 
in 2 mL complete growth medium. Cultures were incubated with or without the addition 
of PBS, CTB, or CTB-KDEL (1µM) at 37°C for 24 h. Thereafter, the supernatant was 
aliquoted and stored at −80°C, tissues were washed in complete medium and 
27 
 
homogenized for gene expression analysis, formalin-fixed for histopathology, or frozen 
in liquid nitrogen for additional analysis as necessary.  
 
Statistics. For all data, outliers were determined by statistical analysis using the Grubb’s 
test (P < 0.05) and excluded from further analysis. Graphs were prepared and analyzed 
using GraphPad Prism version 5.0 (GraphPad Software, La Jolla, CA). To compare two 
data sets, an unpaired, two-tailed Student’s t test was used. To compare three or more 
data sets, one-way ANOVA with Bonferroni’s multiple-comparison post-test or Kruskal–
Wallis test with Dunn’s multiple comparison post-test were performed. For body weights 
and DAI results, a two-way ANOVA with Bonferroni’s multiple-comparison post-test 
was employed. A P value of < 0.05 was considered significant. 
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CHAPTER 3: A MODIFIED CHOLERA TOXIN B SUBUNIT CONTAINING AN ER 
RETENTION MOTIF ENHANCES COLON EPITHELIAL REPAIR VIA AN 
UNFOLDED PROTEIN RESPONSE3 
 
 
3.1 Introduction 
Cholera toxin (CT) is classified as an AB5 toxin composed of one A subunit 
(CTA) and a pentameric B subunit (CTB) [106, 107]. In the gut, CT binds to GM1 
ganglioside, via CTB, located on the plasma membranes of epithelial cells that line the 
luminal surface [36-39]. CTB contains five GM1 binding sites that lie on the outer edge 
of each B subunit [28, 53]. Once CT is bound to GM1 ganglioside (up to five 
gangliosides at once), it is endocytosed and trafficked via retrograde transport to the 
endoplasmic reticulum (ER) [52]. Once in the ER, the catalytic domain of CTA (CTA1) 
is dissociated from CTB by protein disulfide isomerase. Subsequently, CTA1 enters the 
cytosol via the ER-associated degradation pathway and returns to the inner surface of the 
plasma membrane to cause water secretion and diarrhea [28, 51, 107]. Meanwhile the fate 
of CTB after dissociation with CTA1 in the ER is not well understood. We have recently 
created a variant of CTB with a C-terminal ER retention motif (CTB-KDEL; previously 
termed CTBp; [89]), which was demonstrated to possess GM1-binding affinity and oral 
 
3 Modified from: FASEB J. 2019 Sep 27:fj201901255R. doi: 10.1096/fj.201901255R. 
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immunogenicity that are virtually equivalent to CTB. Additionally, we found that CTB-
KDEL could mitigate dextran sodium sulfate (DSS)-induced acute colitis and reduced 
tumor development in an azoxymethane (AOM)/DSS model of colitis associated colon 
cancer in mice [50]. These effects were associated with increased TGFβ expression and 
activation, although the mechanism by which CTB-KDEL upregulated TGFβ remained 
elusive. While investigating the mechanistic principle, we recently discovered that the 
epithelial wound repair effects observed in the aforementioned studies are unique to 
CTB-KDEL and not attained by CTB. The ER-retention motif was initially added to CTB 
to improve recombinant production in tobacco plants (Nicotiana benthamiana), which 
aided in reducing ER stress that otherwise caused poor production yield [42, 89]. It was 
thought that the KDEL sequence helped prolong CTB-KDEL’s residence time in the ER 
within plant cells to allow for proper folding and assembly. Additionally, the protein ER 
retention mechanism involving the KDEL receptor is highly conserved among eukaryotic 
organisms [102]. Thus, the plant-made protein’s C-terminal ER retention signal sequence 
KDEL, added to improve the protein’s production in planta, could theoretically alter the 
protein’s fate upon entering mammalian cells [52, 54, 107], which in turn might explain 
the unique colon mucosal healing activity of CTB-KDEL.   
Here we investigated how the artificial ER-retention motif of CTB-KDEL 
contributes to the protein’s mucosal healing activity in in vitro cell culture and in vivo 
mouse DSS acute colitis. The results have led to the discovery that an unfolded protein 
response (UPR) plays a critical role in the induction of intestinal mucosal healing, 
providing implications for novel therapeutic approaches for IBD.    
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Table 1.  
Recombinant CTB variants used in the present study 
Protein Name C-terminal KDEL sequence Production System 
CTB No Escherichia coli BL21(DE3) 
CTB-KDEL Yes Nicotiana benthamiana 
CTB-KDE Lacking the terminal Leu 
residue 
Escherichia coli BL21(DE3) 
eCTB-KDEL Yes Escherichia coli BL21(DE3) 
G33D-CTB-KDEL Yes Nicotiana benthamiana 
 
 
3.2 Results 
 
3.2.1 The C-Terminal KDEL Sequence is Essential for the Colon Epithelial Repair 
Activity of CTB-KDEL. 
To first determine if the previously described colon mucosal healing effect is 
unique to CTB-KDEL, we employed a human colon epithelial cell line Caco2 model of 
wound healing [50]. Cell migration (i.e., “wound closure”) over 48 h was tested using 3 
µM of CTB-KDEL, CTB, or PBS. As shown in Figure 2A-C, the results revealed that 
CTB had no effect beyond the natural healing response noted in the PBS-treated group, 
while CTB-KDEL treatment significantly enhanced wound closure both at 24 and 48 h 
post wounding similarly to the recombinant TGFβ positive control (Figure 2B). This 
enhanced cell migration effect was observed in a broad concentration range of CTB-
KDEL, from 3 µM down to 0.1 µM. On the other hand, CTB had no effect at the same 
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concentrations tested (Figure 2C). We have previously demonstrated in the same model 
that CTB-KDEL’s cell migration effect is mediated by TGFβ, as an anti-TGFβ antibody 
completely inhibited the effect [50]. Thus, TGFβ levels in the culture supernatants were 
measured using a multiplex bead array. In contrast to CTB, CTB-KDEL significantly 
increased TGFβ1 and TGFβ2 levels 24 hours post-wounding (Figure 2D). To rule out the 
possibility that the difference observed between CTB-KDEL and CTB was the result of 
differential binding to Caco2 cells, we performed a flow cytometry analysis where Caco2 
cells were treated with 1 µM CTB-KDEL or CTB. Both CTB-KDEL and CTB showed 
high and similar binding, with > 75% of Caco2 cells showing positive (Figure 2E). 
Consistent with these results, CTB-KDEL and CTB have shown comparable GM1-
binding affinity in ELISA, surface plasmon resonance, and flow cytometry analysis using 
the mouse macrophage cell line RAW264.7 [89].  Together, these results indicate that 
CTB-KDEL, but not CTB, facilitates TGFβ-mediated epithelial wound healing in the 
Caco2 model. Since CTB-KDEL and CTB equally bound to the epithelial cell, the 
discrepancy can be attributed to distinct intracellular events, likely triggered upon their 
internalization and retrograde transportation.     
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Figure 2. CTB-KDEL, but not CTB, enhances cell migration and TGFβ levels in a 
human colon epithelial cell wound healing model. Caco2 cells were grown to 
confluence and scratched with a pipette tip. Cells were then incubated with PBS, CTB, 
CTB-KDEL, or TGFβ1. The in vitro wound closure was recorded over 48 h and 4x 
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magnification images were acquired with the EVOS® FL imaging system (Advanced 
Microscopy Group) and mean percentage closure was determined by Image J software. 
(A) Representative photomicrographs of Caco2 cells treated with PBS, CTB-KDEL or 
CTB at 0 and 24 h post scratch. (B) Analysis of “wound closure” induced by 3 µM CTB-
KDEL or CTB, or 0.2 nM (or 5 ng/mL) TGFβ1 over 48 h, compared to a PBS vehicle 
control. (C) Percent increase in “wound closure” by varying concentrations of CTB or 
CTB-KDEL compared to PBS after 24 h. (D) TGFβ1 and TGFβ2 protein concentrations 
in Caco2 cell supernatants. (E) Caco2 cell flow cytometry analysis. Cells (1 x 105) were 
treated with 1 µM CTB or CTB-KDEL, or PBS for 15 min on ice, then fix and stained 
with a rat anti-CTB monoclonal antibody. (F) Percent increase in “wound closure” by 1 
µM of CTB-KDEL, CTB-KDE or CTB compared to PBS after 24 h. Bars represent mean 
± SEM of four independent analyses. One-way ANOVA with Bonferroni’s multiple 
comparison tests was used to compare all pairs of groups (B – E). Significantly different 
pairs are highlighted with asterisks (*, **, ***P < 0.05, 0.01, 0.001). 
  
The above results led us to hypothesize that the C-terminal KDEL sequence is 
essential to CTB-KDEL’s wound healing activity. To further delineate the importance of 
the ER retention motif, a variant lacking the C-terminal Leu residue (CTB-KDE) was 
made. As shown in Figure 2F, CTB-KDE failed to promote wound healing unlike CTB-
KDEL in a Caco2 cell wound healing assay.  Additionally, in order to rule out the 
possibility that the unique activity is not attributed to the Nicotiana benthamiana 
production system, CTB-KDEL was produced in Escherichia coli (eCTB-KDEL) and 
tested in the Caco2 cell wound healing assay. Indeed, e CTB-KDEL significantly 
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promoted wound healing 24 hours post-wounding in contrast to the non-KDEL 
counterpart (Figure 3).  
 
 
Figure 3. Escherichia coli produced CTB-KDEL enhances cell migration. Caco2 cells 
were grown to confluence and scratched with a pipette tip. Cells were then incubated 
with PBS, eCTB-KDEL, or CTB. The in vitro wound closure was recorded over 24 h and 
4x magnification images were acquired with the EVOS® FL imaging system (Advanced 
Microscopy Group) and mean percentage closure was determined by Image J software 
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Figure 4. Stability of CTB and CTB-KDEL in Caco2 cells. (A) After 4 h incubation 
with 2 µM of CTB or CTB-KDEL, Caco2 cells were washed with EMEM, and then, cells 
were lysed at different timings (0, 12 and 24 h). Anti-CTB antibodies showed CTB and 
CTB-KDEL proteins in western blot (Anti-CTB) and actin antibodies detected actin 
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proteins (Anti- β-Actin). (B) Immunofluorescence analysis of CTB-KDEL or CTB 
intracellular localization within the ER. CTB-KDEL accumulates within Caco2 cells in 
contrast to CTB.  Caco2 Cells were treated with 1µM PBS, CTB, or CTB-KDEL for 6 or 
24 hours. Cells were fixed/permeabilized and stained with anti-CTB mAb detected by 
Alexa FluorTM 488 (green), ER-selective red dye (red), and DAPI (blue).  Slides were 
analyzed by wide-field fluorescence confocal microscope (60x magnification, Z-stacked 
images). Scale bars = 20 µm. (A) Performed by Dr. Youngjun Oh 
 
We next explored if the ER retention motif of CTB-KDEL has any influence on 
the protein’s residence within epithelial cells. Due to the known function of KDEL 
receptors (KDELR) [108-110], it was hypothesized that CTB-KDEL could localize and 
remain in the ER for an extended period after retrograde transport [54]. To test this 
hypothesis, Caco2 cells were treated with CTB-KDEL or CTB then washed and 
incubated for 0, 12, 24 hours, followed by an immunoblot analysis to detect CTB and 
CTB-KDEL in the cell lysates. As shown in Figure 4A, CTB-KDEL was continuously 
detected in the cell lysates over 24 h, whereas CTB showed decreasing levels, with only a 
marginal amount detected at 24 h post treatment. To discern the location of CTB-KDEL 
and CTB in the cells, we utilized confocal microscopy, in which cells were treated with 
CTB-KDEL or CTB for 24 h and then fixed and stained for CTB, the ER, the KDELR 
and nuclei. As depicted in Figure 4B, CTB-KDEL was detected much more prevalently 
inside Caco2 cells at 6 and 24 h post treatment. Since CTB-KDEL and CTB showed 
similar binding to the surface of Caco2 cells (Figure 2E), it is likely that the difference in 
their amounts detected within Caco2 cells occurred after internalization. Confocal 
microscopy showed the colocalization of CTB-KDEL and KDELR 24 h post treatment, 
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while CTB was hardly detected (Figure 5A). This was also corroborated by a proximity 
ligation assay (PLA), which reveals protein-protein interactions that are within a 40 nm 
proximity [111] (Figure 5B & C). The interaction of CTB-KDEL, CTB-KDE or CTB 
with KDELR in Caco2 cells was also confirmed by co-immunoprecipitation (Figure 5D). 
Rat anti-CTB antibody slightly preferred to original CTB than CTB-KDE and CTB-
KDEL. It seems to cause by structural and electronic hindrances from positive and 
negative charged residues in KDE. While CTB-KDEL showed clear binding to the 
KDELR, such interaction was not observed with CTB or CTB-KDE. Collectively, these 
results demonstrate that CTB-KDEL has a prolonged residence within Caco2 cells due to 
its interaction with the KDELR.   
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Figure 5. CTB-KDEL binds to the KDEL receptor (KDELR). (A) 
Immunofluorescence analysis of CTB-KDEL or CTB intracellular localization within the 
ER. Caco2 Cells were treated with 1 µM of CTB or CTB-KDEL, or a vehicle control 
(PBS) for 24 h. Cells were fixed/permeabilized and stained with an anti-CTB monoclonal 
antibody detected by Alexa FluorTM 488 (green), Anti-KDEL polyclonal antibodies 
(red), and DAPI (blue). (B) Proximity ligation assay (PLA) of CTB-KDEL or CTB 
protein-protein interaction with KDELR within the ER. Caco2 Cells were treated with 1 
µM of CTB or CTB-KDEL, or a vehicle control (PBS) for 24 h. (A, B) Slides were 
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analyzed by wide-field fluorescence confocal microscope (60x magnification, Z-stacked 
images). (C) PLA signals per cell (n = 3). (D) Co-immunoprecipitation (Co-IP) of KDEL 
receptor with CTB or CTB-KDEL.  Caco2 cell lysates were incubated with 4 µg of CTB 
or CTB-KDEL for 24 h. Ten % of mixture was presented in total lanes. CTB antibodies 
and Protein A beads were loaded for immunoprecipitation. After 3 wash steps, beads in 
sample buffer were boiled at 95 ℃ for 10 minutes and then, supernatants were loaded in 
IP lanes. (D) Performed by Dr. Youngjun Oh  
 
3.2.2 CTB-KDEL Induces an Unfolded Protein Response and IRE1-XBP1 Signaling in 
Caco2 Cells. 
It is well known that accumulation of aberrant proteins in the ER can lead to an 
unfolded protein response (UPR) and subsequently activate various intracellular signaling 
pathways [112-114]. Such aberrant proteins would usually be unfolded and misfolded 
polypeptides of endogenous origin, but adventitious proteins such as CTB may also 
induce UPR [54, 115]. There are three branches of UPR known in mammalian cells, 
including IRE1 (inositol-requiring enzyme 1), PERK (Protein Kinase Related-like ER 
kinase), and ATF6 (Activating transcription factor 6; α and β isoforms) [116, 117]. 
Among these, the IRE1-XBP1 pathway has been linked to wound healing and mitigation 
of DSS colitis [118-120]. Therefore, we tested whether CTB-KDEL induces UPR and 
IRE1-XBP1 signaling in Caco2 cells. A RT-qPCR analysis showed that, when cells were 
treated with PBS, CTB or CTB-KDEL for 24 h, all three sensors of the UPR pathway 
(ATF6, PERK, IRE1), as well as spliced XBP1 (sXBP1) and TGFB1, were significantly 
upregulated in CTB-KDEL-treated cells when compared to PBS and/or CTB (Figure 
6A). Congruent with the RT-qPCR results, an immunoblot analysis revealed significantly 
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increased IRE1α, phosphorylated IRE1α, PERK, and Binding Immunoglobulin Protein 
(BiP) levels in CTB-KDEL treated cells, but not in PBS, CTB or G33D-CTB-KDEL-
treated cells (Figure 6B & C).  
 
Figure 6. CTB-KDEL induces the unfolded protein response (UPR). Caco2 cells 
were grown to confluence and scratched. Cells were then incubated with PBS, CTB, 
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and/or CTB-KDEL (A) RT-qPCR analysis of UPR gene expression in Caco2 cells 6 h or 
24 h after treatment. One-way ANOVA with Bonferroni’s multiple comparison tests was 
used to compare all pairs of groups. Mean ± SEM is shown for each group (N = 4). (B) 
Immunoblot analysis of ER stress/UPR-related proteins. Caco2 cells were incubated for 
24 h with PBS, 1 µM of G33D-CTB-KDEL (a non-GM1 binding CTB-KDEL mutant), 
CTB, or CTB-KDEL. Two-hundred µg of total protein were loaded for immunoblot 
analysis. β-Actin was used a loading control. A representative image from three 
independent analyses is shown.  (C) The intensities of western blot bands were measured 
by Image J program. All graphs showed relative values and error bar means standard 
deviation (n=3). (D) Co-immunoprecipitation of BiP with CTB or CTB-KDEL. For 1 
hour or 24 hours, Caco2 cells were incubated with 1 µM CTB and 1 µM CTB-KDEL. 20 
% of intracellular extracts were loaded in total lanes (Total 20 %). Intracellular extracts 
were incubated with 4 µg of BiP antibodies for 2 h at 4 ℃. Ten µl of Protein A beads 
were employed to precipitate the binding complex of BiP. After washing, samples were 
loaded in immunoprecipitation lanes (IP). Anti-CTB antibodies showed CTB and CTB-
KDEL proteins in western blot (Anti-CTB) and BiP antibodies detected BiP proteins 
(Anti-BiP). (E) Co-immunoprecipitation of IRE1 α with BiP. For 24 hours, caco-2 cells 
were incubated with PBS buffer (PBS), 1 µM G33D CTB mutants (G33D CTB-KDEL), 
1 µM CTB, and 1 µM CTB-KDEL. 10 % of intracellular extracts were loaded in total 
lanes (Total 10 %). Intracellular extracts were incubated with 4 µg of IRE1α antibodies 
for 2 h at 4 ℃. Ten µl of Protein A beads were employed to precipitate the binding 
complex of IRE1 α. After washing, samples were loaded in immunoprecipitation lanes 
(IP). Anti-IRE1 α antibodies showed IRE1 α proteins in western blot (Anti-IRE1α) and 
BiP antibodies detected BiP proteins (Anti-BiP). (B-D) Performed by Dr. Youngjun Oh  
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The onset of UPR is preceded by the dissociation of BiP from the UPR sensors 
(ATF6, PERK, IRE1), which is caused by the attraction of the molecular chaperone by 
aberrant proteins in the ER [121, 122]. Accordingly, we examined the binding of BiP 
with CTB-KDEL in Caco2 cells. A co-immunoprecipitation assay using an anti-BiP 
antibody revealed that, when the cells were incubated with CTB or CTB-KDEL for 1 h, 
both proteins formed a complex with BiP (Figure 6D). However, after 24 h incubation, 
only CTB-KDEL was shown to interact with the ER chaperone (Figure 6D). These 
results indicate that the CTB domain has the capacity to interact with BiP and that the 
retention of CTB-KDEL in the ER (by the KDELR) prolonged their interaction. To 
confirm this observation, we monitored the amounts of IRE1-BiP complex in a co-
immunoprecipitation assay using an anti-IRE1α antibody after incubating Caco2 cells 
with G33D-CTB-KDEL, CTB or CTB-KDEL, or PBS (Figure 6E). The results revealed 
that the association between BiP and IRE1α was significantly reduced by CTB-KDEL, 
but not by PBS, G33D-CTB-KDEL or CTB.  
43 
 
 
Figure 7. CTB-KDEL’s epithelial wound healing activity is mediated through IRE1-
XBP1 signaling. (A) Caco2 cells were grown to confluence and scratched with a pipette 
tip. Cells were then incubated with PBS, CTB, CTB-KDEL, and/or 4µ8C. Wound closure 
over 24 h was analyzed. Mean percentage closure was determined by Image J software (n 
=4). (B) TGFβ concentrations in Caco2 cell supernatants from wound healing assay in 
(A). Mean ± SEM is shown for each group (N = 4). (C) Impact of XBP1-knockdown on 
CTB-KDEL’s wound healing activity. Caco2 cells (n=6) were transfected with control 
siRNAs (siCon) or XBP1-targeted siRNAs (siXBP1). After 72 h, cells were scratched 
and treated with 1 µM of CTB or CTB-KDEL. The wound closure was measured at 24 h. 
(D) The transcript levels of XBP1 were measured by qRT-PCR, using 18S rRNA as a 
reference. (A – D) *, **, *** P < 0.05, 0.01 and 0.001: One-way ANOVA with 
Bonferroni's multiple comparison tests. (C-D) Performed by Dr. Youngjun Oh 
Collectively, the above findings strongly suggest that CTB-KDEL’s prolonged 
residence in the ER induces a UPR in Caco2 cells, which may be in part due to the 
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protein’s interaction with the ER chaperone BiP. To test the impact of the UPR on CTB-
KDEL’s wound healing effect, we treated Caco2 cells with CTB-KDEL in the presence 
or absence of 4µ8C, an inhibitor of IRE1-mediated XBP1 splicing (and hence inhibits the 
activation IRE1-XBP1 signaling pathway [123]), after scratching the cell monolayer. The 
analysis revealed that 4µ8C completely blocked CTB-KDEL’s cell migration effects; 
whereas CTB-KDEL treatment significantly enhanced wound closure, CTB-
KDEL+4µ8C and 4µ8C treated groups showed no effect compared to the PBS control 
group (Figure 7A). Furthermore, as shown in Figure 7B, CTB-KDEL treatment 
significantly increased TGFβ1 and TGFβ2 levels when compared to PBS, CTB-
KDEL+4µ8C or 4µ8C treatment, indicating that CTB-KDEL increases TGFβ1 and 
TGFβ2 levels and subsequent cell migration via the IRE1-XBP1 signaling pathway. 
These results are further supported by an XBP1 knock-down experiment, where Caco2 
cells were transfected with control siRNAs (siCon) or XBP1-targeted siRNAs (siXBP1) 
and then cells were scratched and treated with CTB-KDEL or CTB. The results clearly 
showed that siXBP1 treatment significantly reduced CTB-KDEL-induced upregulation of 
XBP1 levels as well as cell migration activity (Figure 7C, D).   
 
3.2.3 CTB-KDEL Induces A UPR in Primary Colon Epithelial Cells and Facilitates 
Colonic Wound Healing After DSS-Induced Acute Colitis in Mice 
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Figure 8. Immunoblot analysis of UPR-related proteins. Mouse primary colon 
epithelial cells were incubated for 24 h with PBS, or 1 µM of G33D-CTB-KDEL (a non-
GM1 binding CTB-KDEL mutant), CTB or CTB-KDEL. (A) Two-hundred µg of total 
protein were loaded for immunoblot analysis. β-Actin was used a loading control. A 
representative image from three independent analyses is shown. (B) The band intensities 
of western blot bands were measured by Image J. All graphs show relative values and 
bars represent mean ± SEM (n=3). (A-B) Performed by Dr. Youngjun Oh  
 
To determine if the above-described mechanism by which CTB-KDEL induces 
cell migration in vitro is applicable to intestinal wound healing in vivo, we isolated and 
treated mouse primary colon epithelial cells with PBS, CTB-KDEL, CTB or G33D-CTB-
KDEL for 24 h. An immunoblot analysis revealed that CTB-KDEL significantly 
increased IRE1α, phosphorylated IRE1α (p-IRE1α), PERK and BiP levels compared to 
all other treatment groups (Figure 8A, B). Albeit to a lesser extent, CTB also 
significantly increased the levels of IRE1α and BiP when compared to PBS; however, 
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CTB did not increase the p-IRE1α level. Next, we employed a mouse acute DSS colitis 
model to compare the wound healing efficacies of CTB-KDEL and CTB. Female 
C57bl/6 mice were given one dose of PBS, 3 µg CTB-KDEL or 3 µg CTB via gavage 
after a 7-day 3% DSS exposure period (Day 7), at which the onset of colonic epithelial 
damage had taken place [97]. As shown in Figure 8A, CTB-KDEL-dosed mice showed a 
significantly more rapid recovery from DSS-induced weight loss than PBS and CTB-
dosed groups. This trend was noted as early as 3 days post administration (Day 10) 
through Day 14 at which the mice were sacrificed. The recovery in body weight was 
accompanied by a significant protection from colon shrinkage as well as significant 
decrease in disease activity index (DAI) and histopathological crypt scores at sacrifice in 
CTB-KDEL-administered animals (Figure 8B). Furthermore, a complete blood count 
analysis of terminal blood samples (collected on Day 14) showed that CTB-KDEL 
treatment significantly reduced the DSS-induced escalation of monocyte, basophil and 
eosinophil levels compared to PBS-dosed mice. Neutrophil levels were significantly 
higher in PBS and CTB-dosed mice compared to those of the healthy control animals, but 
not in CTB-KDEL-dosed animals (Figure 8C). Similar results were also obtained in 
male C57bl/6 mice, in which CTB-KDEL, but not CTB, significantly facilitated recovery 
from acute DSS colitis on the basis of DAI, colon length and crypt scores, suggesting that 
there is no sex-related difference in the therapeutic effects of CTB-KDEL (Figure 8D).  
Additional histopathological examination on hematoxylin and eosin (H&E)-stained distal 
colon tissues of the female mice revealed that CTB-KDEL treatment protected from 
ulceration, inflammation and loss of colonic epithelial surface and crypts, in contrast to 
PBS and CTB treatment (Figure 10A). Moreover, immunohistochemistry (IHC) staining 
for an epithelial marker, E-cadherin [124, 125], on the same tissues used for 
47 
 
histopathological examination, clearly revealed that CTB-KDEL-treated mice had an 
epithelial surface that has recovered (or maintained) near-normal thickness, with ongoing 
crypt regeneration noted throughout the tissue (Figure 10A). Consistent with these 
findings, a RT-qPCR analysis revealed that CTB-KDEL administration significantly 
upregulated multiple genes associated with epithelial repair, including Cdh1, Wnt5a, and 
Col5a3 (Figure 10B) [126-129].  Collectively, these results demonstrate CTB-KDEL’s 
unique ability to mitigate DSS-colitis and facilitate epithelial repair in mouse colons. 
Given that CTB-KDEL activated an UPR in primary mouse colon epithelial cells (Figure 
8), the enhanced epithelial repair was likely mediated via the UPR, or specifically the 
IRE1 pathway, as demonstrated in the Caco2 model (Figure 7).   
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Figure 9. Effects of orally administered CTB or CTB-KDEL in an acute DSS-colitis 
model. Mice (female and male C57BL/6J, 9-week old) were exposed to 3% DSS for 
seven days and orally administered with PBS, CTB, or CTB-KDEL on the 7 seventh day. 
Colon tissues were isolated after a 7-day recovery for analyses. Mean ± s.e.m. is shown 
for each group. N = 10 Animals per group. (A) Female mice percent change of body 
weights. Animals were weighed daily and just prior to the initiation of DSS exposure. 
Percent change was based on the initial body weight. *P < 0.05 between DSS-exposed, 
CTB-KDEL and PBS-administered groups, #P < 0.05 between DSS-exposed, CTB-
KDEL and CTB-administered groups; two-way ANOVA with Bonferroni’s multiple 
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comparison tests. (B) Top-Right: Female mice disease activity index (DAI) scores 
calculated from body weight loss, fecal consistency and occult blood scores at the time of 
sacrifice. Bottom-left: Colon length measured at sacrifice. Bottom right: Colon crypt 
scoring from paraffin embedded tissue sections were scored after staining with 
Hematoxylin and Eosin (H&E). Scoring was based on 0–4 scale. Top-right: Colon length. 
(C) Female mice complete blood count analysis performed at the time of sacrifice. Mean 
± SEM is shown for each group (N = 5). (D) Male mice (male C57BL/6J, 9-week old) 
DAI scores, colon length and colon crypt score. Mean ± s.e.m. is shown for each group N 
= 10. Bonferroni’s multiple comparison tests was used to compare all pairs of groups (A, 
B, C, D). Significantly different pairs are highlighted with asterisks (*P < 0.05, **P < 
0.01, and ***P < 0.001). 
50 
 
 
Figure 10. CTB-KDEL and CTB effects on mouse colon histological alterations 
induce by DSS-colitis. CTB-KDEL treatment protected mice from ulceration, 
inflammation and loss of colonic epithelial surface and crypts. (A) Top: representative 4x 
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(left) and 10x (right) photomicrographs of H&E stained distal colon tissues from each 
treatment group. Bottom: Immunohistochemistry (IHC) staining of E-cadherin positive 
cells in distal colon tissue, representative photomicrographs are shown. (B) qRT-PCR 
analysis of cytokine gene expression in mouse colon tissue. Mean ± SEM is shown for 
each group (N = 4). 
 
3.3 Discussion 
Here we aimed to delineate the mechanism by which CTB-KDEL exhibits unique 
colon epithelial wound repair activity that has not been previously observed with CTB. 
Our data reported herein demonstrated that it is ascribed to the C-terminal ER retention 
motif, which was added initially to improve the yield of the cholera vaccine antigen by 
means of accumulation in the ER of host plant cells upon transient overexpression [107]. 
However, the KDELR is highly conserved among eukaryotic organisms, including plant 
and mammalian cells, signifying that CTB-KDEL could interact with the receptor within 
human IECs. Once bound to KDEL-containing proteins, the receptor transports proteins 
from the Golgi apparatus to the ER [52, 54, 102]. It has been previously shown that 
KDELR-mediated retention of proteins in the ER can lead to a UPR in human cells [130, 
131]. Meanwhile, a UPR has been linked to TGFβ activation in hepatocytes, skin 
fibroblasts and lung epithelial cells [132-134]. Consequently, it is deemed reasonable that 
CTB-KDEL induces TGFβ signaling via a UPR in IECs, leading to the new function of 
mucosal wound healing in colitis models. Our data provide multiple lines of evidence to 
support the above notion. First, a variant of CTB-KDEL that lacks the terminal leucine 
residue (CTB-KDE) failed to induce cell migration in Caco2 cells (Figure 2). Second, 
CTB-KDEL colocalized with KDELR and remained longer than CTB within the ER of 
52 
 
Caco2 cells (Figures 4 and 5). Previous studies investigating the intracellular trafficking 
of CT and CTB have shown that CTB’s retrograde transportation is triggered upon 
binding to cell-surface GM1-ganglioside, which allows the proteins to reach deep 
endomembrane compartments and the ER [54, 135]. As shown in Figures 4 and 5, both 
CTB and CTB-KDEL were found in the ER, however, the latter was more consistently 
retained and localized within the ER, likely due to its capacity to interact with the KDEL 
receptor. Third, CTB-KDEL, but not CTB, increased the levels of UPR sensors by 1.5 – 
2-fold in Caco2 and mouse primary colon epithelial cells (Figures 6 and 8). Finally, 
genetic and chemical inhibition of IRE1-XBP1 signaling completely abolished the TGFβ 
upregulation and cell migration effects of CTB-KDEL in Caco2 cells (Figure 7). 
Combined with our previous data showing that GM1 binding is essential for CTB-
KDEL’s wound healing effect in Caco2 cells [50], these data strongly suggest that the C-
terminal KDEL sequence rendered CTB-KDEL with a unique new wound healing 
activity in the colon epithelial cells.  
Accumulation of aberrant proteins in the ER promotes the dissociation of BiP 
from the three main ER transmembrane sensors, IRE1, PERK and ATF6, which triggers 
their dimerization and phosphorylation for the activation of sensor signal transduction 
leading to the UPR [116, 136, 137]. Our data demonstrated that CTB-KDEL indeed 
interacted with BiP, which in turn induced the dissociation of BiP from IRE1 complex 
(Figure 6). Therefore, it is likely that the binding of CTB-KDEL to BiP plays a role in 
the initiation of UPR seen with CTB-KDEL treatment. IRE1 represents the most 
evolutionarily conserved branch of the UPR that is made up of two isoforms, IRE1α and 
IRE1β, of which IRE1β is unique to the epithelium of the digestive and respiratory tract 
[138]. IRE1-XBP1 signaling has been linked to TGFβ activation, wound healing, colon 
53 
 
epithelial cell prosurvival signaling, and protection from DSS-induced colitis, as 
mentioned previously [118, 120, 132, 133, 139].  In this regard, CTB-KDEL significantly 
increased IRE1α expression 6 h after treatment and all 3 arms of UPR sensors (ATF6, 
PERK, and IREI), as well as the IRE1 signal transducer XBP1, 24 h after treatment 
(Figure 6). Furthermore, inhibition of IRE1 signaling by the chemical inhibitor 4µ8C 
completely blocked the wound healing activity of CTB-KDEL as well as CTB-KDEL-
mediated TGFβ1 and TGFβ2 induction (Figure 7) indicating that CTB-KDEL’s wound 
healing activity is mediated through IRE1 signal transduction. Of note, UPR activation is 
closely linked to ER stress and apoptotic pathways [138]. However, we did not observe 
any cytotoxic response to CTB-KDEL up to 10 µM (0.61 mg/mL) in Caco2 cells (Figure 
2), suggesting that the protein did not overstimulate UPR beyond the threshold for a cell 
death response. In our preliminary study using polarized T84 cell monolayers, we found 
that the levels of UPR marker genes induced by CTB-KDEL were significantly lower 
than the well-known UPR inducer thapsigargin (data not shown). It is possible that the 
amount of cell-surface GM1 ganglioside was a limiting factor, whereby the receptor 
became saturated before the concentration of CTB-KDEL reached a point that overload 
the ER. Further investigation is necessary to understand CTB-KDEL’s impacts on UPR, 
ER stress and survival in epithelial cells. 
In the mouse DSS acute colitis model, a single oral administration of as little as 3 
µg of CTB-KDEL significantly enhanced recovery from colitis (Figures 9 and 10). The 
therapeutic effects were characterized by enhanced epithelial regeneration, demonstrated 
by E-cadherin IHC and upregulated Cdh1 and Wnt5a levels, suggesting that the rapid 
resolution of epithelial injury is the primary mechanism of CTB-KDEL’s efficacy in this 
model. It should be noted that CTB failed to show such effects and was essentially futile 
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in this model. This is in sharp contrast to previous findings by Boirivant et al., which 
showed that oral administration of CTB can resolve TNBS (2,4,6-trinitrobenzenesulfonic 
acid)-induced colitis via Th1 cell inhibition [70, 77]. Although a direct comparison 
cannot be made due to two different colitis models, the discrepancy in CTB’s efficacies 
could be in part explained by the different dose amounts and timings employed in those 
two studies; whereas Boirivant et al. administered 4 daily doses of 100 µg CTB 
immediately after the administration of TNBS [70, 77], we dosed one 3 µg dose of CTB-
KDEL or CTB at the end of DSS exposure. This points to the possibility that the low 
dose of CTB was not sufficient to show a therapeutic effect in the DSS model. 
Conversely, whether CTB-KDEL at high dose levels exhibits T cell-inhibitory effects 
like CTB remains to be determined.   
In DSS-induced colitis model, the epithelium receives a barrage of mucosal 
insults, both physical and chemical that result in the loss of the epithelial barrier and 
damage to the mucosa [95].  Thus, the initial step in injury repair occurs through a rapid 
migration response of the epithelial sheet (termed restitution) [140, 141]. The process 
occurs independently of proliferation and results in depolarization of IECs surrounding 
the wounded area [141]. This depolarization leads to an epithelial-to-mesenchymal 
transition (EMT) where cells adopt a migratory phenotype induced by increased TGFβ 
levels [142, 143]. Previously, we showed that CTB-KDEL induces multiple TGFβ-
dependent EMT pathways after treating mice with CTB-KDEL [50]. However, the TGFβ 
expression level in the CTB-KDEL-dosed animals was not significantly high, although 
upregulated 3-fold, at the time of sacrifice, suggesting that the cytokine had likely passed 
its peak expression point. In fact, we observed a significant upregulation of Serpine1, an 
inhibitor of TGFβ, in the CTB-KDEL-dosed group (data not shown). Additionally, we 
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detected upregulated Cdh1 gene in CTB-KDEL-treated mice (Figure 10), which is 
indicative of a late-phase wound healing involving epithelial proliferation and maturation 
[126, 127, 129, 144, 145]. E-cadherin expression is inversely correlated with TGFβ levels 
due to TGFβ-induced class switching of E-cadherin to N-cadherin which depolarizes 
cells and allows them to become of migratory phenotype [143, 145, 146]. Thus, the 
elevated Cdh1 levels and strong E-cadherin positive epithelial cell staining that lined the 
mucosa of CTB-KDEL-treated mice indicate the repolarization of the epithelial cells, 
increased tightening of mucosal barrier and improved mucosal barrier integrity, which are 
critical steps during epithelial repair [145]. In addition to EMT, TGFβ1 stimulates and 
increases expression of WNT5a [144]. WNT5a has been shown to induce new crypt 
formation and re-establish epithelial homeostasis after injury [144]. The H&E-stained 
tissue sections clearly revealed the regeneration and formation of new crypts in the CTB-
KDEL-dosed group, corroborating the function of upregulated Wnt5a expression in the 
colon mucosa. Taken together, these data strongly support the notion that oral 
administration of CTB-KDEL can facilitate colon epithelial restitution and wound 
healing, at least in the conditions tested in the acute DSS colitis model.  
In conclusion, the data herein reveal that CTB-KDEL exhibits unique colon 
mucosal would healing effects that are mediated by its localization in the ER via KDELR 
and subsequent activation of a UPR and TGFβ signaling in colon epithelial cells. Further 
investigation of the role of the UPR in TGFβ activation in colon epithelial cells may shed 
light on the mechanistic link to epithelial restitution and repair, facilitating the 
development of a new agent for the treatment of inflammatory diseases of the mucosa. 
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CHAPTER 4: REPEATED ORAL ADMINISTRATION OF A KDEL-TAGGED 
RECOMBINANT CHOLERA TOXIN B SUBUNIT EFFECTIVELY MITIGATES DSS 
COLITIS DESPITE A ROBUST IMMUNOGENIC RESPONSE4 
 
 
4.1 Introduction 
The principal virulence factor of Vibrio cholerae is cholera toxin (CT), which is 
comprised of a toxic A subunit and a non-toxic homopentameric B subunit (CTB). 
Recently, we have shown that a recombinant variant of CTB containing a KDEL 
endoplasmic reticulum (ER) retention motif (CTB-KDEL) has the ability to induce 
mucosal healing, facilitate colon epithelial wound repair, and enhance recovery from an 
acute dextran sulfate sodium (DSS) colitis model in mice [50, 147]. These effects were 
attributed to the addition of the C-terminal ER retention motif, KDEL, to CTB. The 
KDEL sequence enabled CTB-KDEL to bind to the KDEL receptor and localize within 
the ER in the Caco2 human colon epithelial cell line. Upon ER localization, CTB-KDEL 
induced an unfolded protein response (UPR) and subsequent TGFβ signaling. In 
particular, the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1) arm 
of the UPR was indispensable for wound healing activity  [147]. These findings were 
 
4 Modified from: Toxins (Bacterial Enterotoxins). 2019 Nov 18; 11(12), 678. 
https://doi.org/10.3390/toxins11120678 
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corroborated in primary mouse colon epithelial cells, where CTB-KDEL induced an 
UPR, while CTB and the non-GM1 binding mutant G33D-CTB-KDEL failed to exhibit 
such an effect. Moreover, in an ex vivo experiment using colectomy tissue from 
inflammatory bowel disease (IBD) patients, CTB-KDEL, but not CTB, induced an UPR, 
upregulated wound healing pathways, and maintained viable crypts [147]. These findings 
provide implications for the potential use of CTB-KDEL in the treatment of IBD. 
It is estimated that 1.3% of US adults (3.1 million) suffer from IBD, which 
consists of two main classes, ulcerative colitis (UC) and Crohn’s disease (CD). IBD is 
characterized by chronic periods of remission and relapse [148]. UC mainly affects the 
mucosa in the rectum and colon, whereas the inflammation in CD affects all layers of the 
bowel wall including the muscularis and serosa. Moreover, unlike UC, inflammation in 
CD can occur at any part of the gastrointestinal (GI) tract [5]. Multiple studies using 
immunosuppressive agents have led to a general consensus that healing of the mucosal 
layer (i.e., mucosal healing) is the most important treatment goal of IBD [13, 14, 19]. In 
particular, the most critical component of the mucosal healing in UC, which does not 
usually involve transmural inflammation, may be epithelial healing/restitution [19]; an 
effect that could be attained by oral administration of CTB-KDEL. Currently, treatment 
strategies for UC aim to blunt the inflammatory response and establish remission by 
employing anti-inflammatory and immunomodulatory agents such as 5-aminosalicylic 
acid, steroids, and thiopurines. However, 20–40% of patients lose response or are 
nonresponders to these agents, which will lead to the use of biologics (i.e., anti-TNF 
agents) that may cause more severe adverse reactions, or surgical resection of the colon 
[3]. Given that nearly half of patients fail to achieve mucosal healing with available 
58 
 
medications [11], we hypothesize that CTB-KDEL may provide a novel therapeutic 
option to achieve the major goal in UC treatment.  
Although oral administration of CTB-KDEL has shown great promise in an acute 
DSS colitis mouse model, it is yet to be determined whether the treatment can reverse 
chronic colitis after it has been established. Acute DSS-induced colitis typically only 
incorporates features of innate immunity and acute epithelial injury [96]. In contrast, the 
chronic and progressive model of colitis induced by repeated exposure to DSS represents 
a complex interplay between innate immune responses and compromised epithelial 
barrier function that drives a chronic sustained inflammatory response [96, 149, 150].  
Another potential issue for the therapeutic use of CTB-KDEL is that the parent 
molecule, CTB, is a strong mucosal immunogen [33-35]. In fact, CTB is used as a 
component of the World Health Organization (WHO) pre-qualified oral cholera vaccine 
Dukoral® to stimulate the production of both secretory immunoglobulin A (S-IgA), 
produced locally in the intestines, and serum immunoglobulin G (IgG) against CT [107, 
151]. CTB’s ability to induce a potent S-IgA and IgG response upon mucosal 
administration is attributed to the various cell types within the GI tract that present GM1 
ganglioside on their cell surface, such as macrophages, dendritic cells (DCs), B cells, T 
cells, neurons, and epithelial cells [36-39]. Previously we have determined that CTB-
KDEL’s immunogenicity is equivalent to that of CTB in mice [89]. From a drug 
development standpoint, the induction of anti-drug antibodies (ADAs) is generally 
regarded as a risk because they could provoke clinical complications that arise from 
altered pharmacokinetics, pharmacodynamics, and/or immunotoxicity [152, 153]. 
However, it is yet to be determined whether immunogenicity is a relevant concern for 
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orally administered biologics, as there are very few such agents that have undergone 
clinical investigation on this matter. 
Here, using the repeated DSS exposure mouse colitis model, we investigated 
whether CTB-KDEL could alleviate chronic colitis and whether the therapeutic effects of 
CTB-KDEL are altered by the protein’s immunogenicity. 
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4.2 Results 
 
4.2.1 CTB-KDEL’s Therapeutic Effects in a Mouse Colitis Model Exposed to Repeated 
DSS Cycles.  
 
 
Figure 11 Dextran sodium sulfate (DSS) chronic colitis study design. Mice were 
exposed to three cycles of DSS that consisted of 2% DSS for seven days followed by 14 
days of normal drinking water. Mice were treated orally with 3 µg of cholera toxin B 
subunit (CTB)-KDEL or vehicle control; PBS, PBS + DSS, and QWd7 mice were dosed 
once a week starting at Day 7, QWd35 mice were dosed once a week starting at Day 35, 
and Q3Dd35 mice were dosed every three days starting at Day 35. Disease activity index 
(DAI) scores were measured daily starting at Day 0. Following euthanasia on day 63, 
colon lengths were measured, serum was collected for fluorescein isothiocyanate (FITC)-
dextran analysis, and distal colon tissues were collected for cytokine quantification and 
histological examination. 
To characterize the therapeutic effect of CTB-KDEL under chronic colitis 
conditions, we performed a chronic DSS colitis experiment in mice in which the animals 
were exposed to three cycles of seven-day DSS exposure followed by 14 days of normal 
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drinking water over 63 days. In this chronic DSS-induced colitis model, mice develop 
chronic inflammation in the colon after the first cycle of DSS exposure [154]. Thus, mice 
were treated orally with 3 µg of CTB-KDEL or vehicle control dosed once a week 
starting at Day 7 (QWd7; before chronic colitis had developed), or dosed every three days 
or QW at Day 35 (Q3Dd35 and QWd35, respectively) (Figure 11). As shown in Figure 
12A, CTB-KDEL QWd7 administration significantly decreased disease activity index 
(DAI) scores immediately following the first dose and maintained significantly lower 
DAI values than the vehicle control-dosed group throughout the study despite exposure to 
two additional DSS cycles. Mice that were treated QWd35 or Q3Dd35 (dosing started after 
chronic colitis was established) also showed immediate reduction in DAI scores 
following CTB-KDEL administration. On Day 63 mice were administered fluorescein 
isothiocyanate (FITC)-dextran by gavage 4 h prior to euthanasia to test the intestinal 
permeability of each group. Chronic DSS-induced colitis is known to induce barrier 
dysfunction followed by increased intestinal permeability that is correlated with 
worsening of the disease [149]. Compared to mice treated with vehicle control (PBS), 
those that received QWd7 and Q3Dd35 CTB-KDEL treatment showed significantly lower 
plasma FITC-dextran levels, indicating that CTB-KDEL treatment improved intestinal 
barrier function (Figure 12B). QWd35 treatment also appeared to have improved the 
barrier function; however, the decrease in FITC-dextran plasma levels was not 
statistically significant. Likewise, with QWd7 and Q3Dd35, but not with QWd35 dosing, 
CTB-KDEL significantly prevented colon shrinkage induced by DSS insult (Figure 
12C). 
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Figure 12. CTB-KDEL mitigates DSS-induced injury and inflammation in a DSS 
chronic colitis study. C57BL/6 mice (n = 10) were exposed to three cycles of seven-day 
2% DSS and 14-day normal drinking water over 63 days and treated with 3 µg CTB-
KDEL or PBS dosed orally every week starting at Day 7 (QWD7) or starting at Day 35 
dosed once a week (QWD35) or every three days (Q3DD35). (A) The time course of disease 
activity index (DAI) values (mean ± S.E.M.) in each group measured from Days 0–63. *p 
< 0.05; two-way repeated measures ANOVA with Bonferroni’s multiple comparison 
tests. (B) FITC-dextran concentrations found in mice serum 4 h after administration on 
Day 63. (C) Colon length measured after Day 63 sacrifice. (D) Proinflammatory 
cytokines in distal colon tissues were measured by Luminex after Day 63 sacrifice. (B, C, 
D) *p < 0.05, **p < 0.01; one-way repeated measures ANOVA with Bonferroni’s 
multiple comparison tests. 
 
To dissect the therapeutic effects of CTB-KDEL, we measured pro-inflammatory 
cytokine levels in the distal colon tissue lysates at the time of euthanasia (Day 63). 
Consistent with other reports of chronic colitis [155, 156], two key markers of chronic 
colitis IL-1β and TNFα were significantly elevated in PBS-treated mice when compared 
to healthy animals (Figure 12D). In contrast, none of the CTB-KDEL treatment groups 
demonstrated an elevation of the pro-inflammatory cytokines tested; IL-1β, TNFα, GM-
CSF, and IFNγ, suggesting an overall suppression of inflammation by CTB-KDEL 
treatment. In particular, QWd7 treatment showed significantly lower GM-CSF and IL-1β 
levels compared to mice treated with PBS + DSS, while QWd35 mice had significantly 
reduced GM-CSF and IFNγ cytokine levels compared to mice treated with PBS + DSS. 
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Although Q3Dd35 dosing did seem to reduce pro-inflammatory cytokine levels, these 
reductions were not statistically significant. 
To further corroborate the above results, we performed a histopathological 
examination and evaluated the presence of active chronic colitis markers, particularly 
crypt structural alterations and expansion of the lamina propria, in hematoxylin and eosin 
(H&E)-stained distal colon tissues. By these metrics, CTB-KDEL-treated mice showed 
increased recovery from chronic DSS-induced colitis compared to vehicle control. QWd7 
and Q3Dd35 dosing demonstrated similar but noteworthy recovery, exhibiting fewer 
instances of crypt branching, crypt distortion, and expansion of the lamina propria than 
QWd35 dosing (Figure 13A). It was indeterminable whether QWd7 or Q3Dd35 dosing had 
the greatest impact on recovery from chronic colitis. QWd35 dosing, however, still 
showed signs of recovery compared to vehicle control, as the latter displayed the most 
severe expansion of the lamina propria and crypt alterations (Figure 13A). These 
histopathological findings were quantified by a crypt score rating of the H&E-stained 
distal colon tissues. As shown in Figure 13B, all CTB-KDEL-treated groups had a 
significantly reduced crypt score, which was characterized by a reduction in the 
shortening or loss of basal crypts and epithelial surface retention in all CTB-KDEL-
treated mice, in contrast to PBS treatment (Figure 13B). 
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Figure 13. Histological findings from the DSS chronic colitis model. CTB-KDEL 
treatment protected mice from inflammation and loss of colonic epithelial surface and 
crypts. (A) Representative 4× photomicrographs of hematoxylin and eosin (H&E)-stained 
distal colon tissues from mice treated with 3 µg CTB-KDEL or PBS dosed orally every 
week starting at Day 7 (QWD7) or starting at Day 35 dosed once a week (QWD35) or every 
three days (Q3DD35) starting at Day 35. Scale bars = 600 µM. (B) Colon crypt scoring 
from paraffin-embedded tissue sections were scored after H&E staining. Scoring was 
based on a 0–4 scale. *p < 0.05, **p < 0.01, ***p < 0.001; one-way repeated measures 
ANOVA with Bonferroni’s multiple comparison tests. 
 
4.2.2 The Impact of CTB-KDEL’s Immunogenicity on its Therapeutic Effect in Acute 
DSS Colitis Models. 
Previously, we have shown that oral administration of 3, 10, or 30 µg CTB-KDEL 
twice at a two-week interval induced anti-toxin serum IgG and fecal IgA antibodies with 
high titers [89]. Notwithstanding, the results in the chronic DSS colitis study shown in 
Figures 2 and 3 demonstrate that repeated dosing with 3 µg of CTB-KDEL (eight doses 
total) did not lose efficacy over the course of the study, raising an interesting question 
about the consequences of an immune response to the protein. Thus, to address this 
immunogenicity question, specifically, the induction of ADAs, we used a mouse model 
of acute DSS colitis in which mice were orally administered with 30 µg of CTB-KDEL 
twice prior to 3% DSS exposure to induce an immunogenic response to the protein (the 
aforementioned vaccine dosing regimen [89]). At the end of DSS exposure, mice were 
orally administered 3 µg of CTB-KDEL; this single therapeutic dose has proven to be 
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efficacious in C57BLl/6J mice [89, 147]. The dosing regimens and groups are depicted in 
Figure 14.  
 
 
Figure 14. Immunogenicity and acute DSS colitis study design. Four groups of mice 
were studied; PBS (healthy vehicle control), PBS + DSS (vehicle control in diseased 
mice), vaccinated + DSS, therapeutic + DSS, and vaccinated + therapeutic+DSS. All 
mice except for Therapeutic + DSS mice were vaccinated with 30 µg CTB-KDEL or PBS 
28 and 14 days (Days −28 and −14) prior to DSS administration. On Day 0, mice were 
given 3% DSS in drinking water for seven consecutive days. On the seventh day of DSS 
exposure, DSS was removed from the drinking water and then PBS, PBS + DSS, 
therapeutic + DSS, and vaccinated + therapeutic + DSS mice were administered with 3 
µg CTB-KDEL or a vehicle control (PBS) in a volume of 100 µL after sodium 
bicarbonate (200 µL of 30 mg/mL solution) administration. Seven days later, on Day 14, 
mice were euthanized (stop sign) and colon lengths and a disease activity index scores 
were measured. Body weights were measured daily and feces were collected on Days 7 
and 14 from each mouse. Black arrows represent the timings of oral administration of 
CTB-KDEL or PBS. 
68 
 
 
As shown in Figure 15A, after DSS exposure was halted all three CTB-KDEL 
dosing regimens showed a significantly more rapid recovery from DSS-induced weight 
loss when compared to PBS-treated mice. Vaccinated + therapeutic + DSS mice showed 
a significant improvement one day after therapeutic dosing (Day 8), while therapeutic + 
DSS and vaccinated + DSS mice showed a significant improvement in weight recovery 
starting at Day 10 and continued throughout the study. These results were confirmed by 
colon length and DAI scores that were examined upon euthanasia at Day 14. The colon 
lengths of both groups therapeutically treated with CTB-KDEL on Day 7 were 
significantly longer than those of the PBS + DSS group (Figure 15B). Additionally, all 
CTB-KDEL treated mice showed similar DAI scores, which were significantly lower 
than those of PBS+DSS mice (Figure 15C). To determine the presence of ADAs in the 
GI tract of these mice, we performed an ELISA detecting CTB-binding IgAs in feces 
collected before (Day 7) and after (Day 14) the therapeutic dose of CTB-KDEL was 
administered. Both vaccinated + DSS and vaccinated + therapeutic + DSS mice had 
similar and high levels of anti-CTB-KDEL IgA antibodies in the intestine on both days, 
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indicating that ADAs were present when CTB-KDEL was administered for the treatment 
of colitis (Figure 15D).  
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Figure 15. The impact of a pre-existing immune response to CTB-KDEL on its 
therapeutic efficacy against DSS acute colitis in C57BL/6 mice. C57BL/6 mice were 
pre-dosed twice orally with 30 µg CTB-KDEL or PBS on Day −28 and Day −14 and then 
exposed to DSS on Days 0–7. A therapeutic dose of CTB-KDEL (3 µg) was dosed orally 
on Day 7. (A) Percent body weight change was monitored daily. Two-way ANOVA with 
Bonferroni’s multiple comparison tests were used to compare groups. *p < 0.05, **p < 
0.01, ***p < 0.001, compared to PBS + DSS group. (B) Colon length measured at 
sacrifice on Day 14. (C) Disease activity index (DAI) at sacrifice on Day 14. *p < 0.05, 
**p < 0.01, ***p <0.001. One-way ANOVA with Bonferroni's multiple comparison tests. 
(D) Fecal anti-CTB-KDEL IgA titers were determined by ELISA on Days 7 (left) and 14 
(right). 
 
To further reveal the impacts of ADAs, we performed the same acute DSS colitis 
experiment in C3H/HeJ mice which, unlike the C57BL/6 strain, are poor responders to 
CTB immunization due to the lack of an MHC haplotype reactive to CTB epitopes [157, 
158]. The experiment was performed exactly as described above (Figure 14) and the 
same dosing groups were implemented. Similar to the results obtained in C57BL/6 mice, 
all three CTB-KDEL dosing regimens proved to be efficacious against DSS colitis in 
contrast to PBS-treated mice (Figure 16). A significant prevention of body weight loss 
was noted in vaccinated + DSS as early as Day 6, while vaccinated + therapeutic + DSS 
and therapeutic + DSS mice demonstrated a significant recovery from body weight loss 
starting on Day 8 (Figure 16A). Furthermore, all CTB-KDEL-treated mice showed 
significantly reduced colon shrinkage and lower DAI scores compared to PBS + DSS 
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mice and were comparable between all CTB-KDEL treatment groups (Figure 16B-C). 
Unlike C57BL/6 mice, however, CH3/HeJ mice had little to no anti-CTB IgA response to
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the vaccination with CTB-KDEL (Figure 16D). Thus, CTB-KDEL’s mucosal therapeutic 
effects in this model are unlikely to be dependent on IgA induction in the intestine. 
 
Figure 16. The impact of CTB-KDEL predosing on its therapeutic efficacy against 
DSS acute colitis in C3H/HeJ mice. C3H/HeJ mice were pre-dosed twice orally with 30 
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µg CTB-KDEL or PBS on Day −28 and Day −14 and then exposed to DSS on Days 0–7. 
A therapeutic dose of CTB-KDEL (3 µg) was dosed orally on Day 7. (A) Percent body 
weight change was monitored daily. Two-way ANOVA with Bonferroni’s multiple 
comparison tests were used to compare groups. *p < 0.05, **p < 0.01, ***p < 0.001, 
compared to PBS + DSS group. (B) Disease activity index (DAI) at sacrifice on Day 14. 
(C) Colon length measured at sacrifice on Day 14. *p < 0.05, **p < 0.01, ***p < 0.001. 
One-way ANOVA with Bonferroni's multiple comparison tests. (D) Fecal anti-CTB-
KDEL IgA titers were determined by ELISA on Day 14. 
 
Finally, to test if  the adaptive immune system is dispensable in CTB-KDEL’s 
therapeutic benefit in the mitigation of DSS colitis we tested the effects of CTB-KDEL in 
Rag1-/- mice, which are deficient in mature B or T cells[159], with the same experimental 
design as performed in C57BL/6 and C3H/HeJ mice (Figures 14, 15, and 16). In contrast 
to C57/BL6 and C3H/HeJ mice, Rag1-/- mice did not show a robust effect in body weight 
by CTB-KDEL treatment (Figure 17). Only Vaccinated+Therapeutic+DSS group 
showed a significant recovery on Day 10 (Figure 17A). Upon sacrifice on Day 14, there 
was no significant difference between the colon lengths of CTB-KDEL treated mice and 
vehicle control group. However, DAI scores of therapeutic+DSS and 
vaccinated+therapeutic+DSS mice were significantly lower than those of PBS+DSS 
treated mice (Figure 17B). When DAI scores were decomposed into individual variables, 
a significant decrease in stool consistency scores was noted in the groups therapeutically 
treated with CTB-KDEL (vaccinated+therapeutic+DSS and Therapeutic+DSS), an 
indicator of decreased intestinal permeability caused by DSS-injury (Figure 17D). There 
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was no significant difference in blood in stool between CTB-KDEL treated and 
PBS+DSS treated mice. These results confirm CTB-KDEL’s therapeutic effect is not 
dependent on a host IgA response; however, further research is needed to determine why 
CTB-KDEL’s effect is not as robust in Rag1-/- mice as C57BL/6 and C3H/HeJ mice. 
 
 
Figure 17. Analysis of CTB-KDEL’s therapeutic efficacy against DSS acute colitis in 
immunodeficient mice. Rag1-/- mice were pre-dosed twice orally with 30 µg CTB-
KDEL or PBS on Day -28 and Day -14 and then exposed to DSS on Days 0 – 7. A 
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therapeutic dose of CTB-KDEL (3 µg) was dosed orally on Day 7. (A) Percent body 
weight change was monitored daily. Two-way ANOVA with Bonferroni’s multiple 
comparison tests were used to compare groups. *P < 0.05, **P < 0.01, ***P < 0.001, 
compared to PBS + DSS group.  (B) Disease activity index (DAI) at sacrifice on Day 14. 
(C) Colon length measured at sacrifice on Day 14. (D) Stool Consistency measured at 
sacrifice on Day 14. (E) Blood in stool measured at sacrifice on Day 14.  *P < 0.05, **P 
< 0.01, ***P < 0.001. One-way ANOVA with Bonferroni's multiple comparison tests. (F) 
Fecal anti-CTB-KDEL IgA titers were determined by ELISA on 14. 
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4.3 Discussion 
 
 
We have previously demonstrated CTB-KDEL’s mucosal healing effects in an 
acute DSS colitis model in C57BL/6 mice and in colonic explants isolated from IBD 
patients, as well as the prevention of tumor development in an azoxymethane 
(AOM)/DSS mouse model of colitis-associated cancer. However, its development as a 
biotherapeutic will need to address unique issues associated with its use. Here we aimed 
to uncover two key questions surrounding CTB-KDEL’s ability to treat chronic 
symptoms of UC. Specifically, we addressed whether CTB-KDEL could resolve colitis 
after the formation of chronic inflammatory conditions in a more clinically relevant 
model based on repeated DSS exposure. Additionally, we determined the impact of 
immunogenicity on CTB-KDEL’s therapeutic efficacy, as the protein is a potent inducer 
of mucosal and systemic antibodies.  
Acute DSS-induced colitis typically only incorporates features of innate immunity 
and acute epithelial injury [160]. In contrast, the chronic and progressive model of DSS 
colitis presented in this manuscript represents a complex interplay between innate 
immune responses and compromised epithelial barrier function that drives a chronic 
sustained inflammatory response [96]. The inflammatory response is driven mainly 
through the paracellular route created by DSS exposure that is exacerbated by 
proinflammatory cytokines, such as TNFα and INFγ [161, 162]. After repeated DSS 
cycles, this proinflammatory response leads to a positive feedback loop of increased 
intestinal permeability, initially driven by DSS, and increased production of 
inflammatory cytokines in response to bacteria that cross the intestinal barrier and 
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inflammatory cytokines that also cause direct damage to the intestinal epithelium [160, 
163, 164]. Apoptosis of intestinal epithelial cells and subsequent damage to intestinal 
mucosa magnifies an increase in intestinal permeability, further adding to the positive 
feedback loop between increased intestinal permeability, enhanced production of 
inflammatory cytokines, and damaged intestinal epithelium. For these reasons, we 
initiated oral CTB-KDEL treatment at two different timepoints during the nine-week 
chronic DSS colitis experiment. One group received the first CTB-KDEL dose at the end 
of the first DSS cycle (i.e., Day 7) when the DSS--induced injury was in the acute phase, 
whereas two other groups initiated CTB-KDEL treatment after the second cycle of DSS 
(i.e., Day 35) when more severe colitis had started to develop. The chronic inflammation 
and histopathogical findings seen in the vehicle control group are similar to the features 
of those seen in human UC [10,35], demonstrating the relevance of this model for the 
purpose of the present study. The data revealed that QWd7 and Q3Dd35 dosing of 3 µg 
CTB-KDEL were more efficacious than QWd35 dosing (Figure 12). Although least 
effective among the three CTB-KDEL treatment groups, the QWd35 dosing group still 
showed efficacy, as evident from significantly low DAI values compared to the untreated 
group throughout the last DSS exposure cycle. Meanwhile, dosing every two weeks was 
not as effective as QW dosing regardless of the timing of initial treatment (data not 
shown). The therapeutic efficacy of CTB-KDEL against chronic colitis was corroborated 
by histological evidence for significant remission and healing in mice treated with the 
protein. In addition, it was also noted that there was minimal neutrophil infiltration in 
tissues of CTB-KDEL-treated mice in contrast to vehicle control (Figure 13). The 
chronic inflammation and histopathological findings seen in our vehicle control group are 
similar to the features of those seen in human UC [96, 165]. Furthermore, these results 
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add to the clinical relevance of the present study because histologic remission and healing 
is an area of increased research focus and holds the promise of being an important marker 
of treatment efficacy in UC [166, 167].  Of note, all CTB-KDEL-dosed groups showed 
reduction in intestinal permeability (serum FITC-dextran levels), downregulation of pro-
inflammatory cytokine levels and decreased histological damage in the colon, all three of 
the main hallmarks of IBD [155, 160, 168].  
The significance of the above results is twofold. First, the results indicate that the 
animals continued to respond to the medication over time. Conversely, CTB-KDEL did 
not lose its efficacy with repeated dosing (eight doses total for QWd7, four doses for 
QWd35, and nine doses for Q3Dd35). Second, as the repeated DSS model usually causes 
chronic inflammation in the colon after the first cycle of DSS exposure [154], the positive 
results in the delayed dosing groups indicate that CTB-KDEL is effective against chronic 
colitis. Collectively, these data provide a basis for both QW and Q3Dd35 dosing to be 
used in the treatment of chronic colitis; QW dosing may be sufficient as a maintenance 
dose to prevent relapse of disease, while Q3D dosing may be better suited for treatment 
of active disease. 
A key pharmacological and toxicological question for biotherapeutic development 
is immunogenicity; specifically, ADA induction. A major disadvantage of therapeutic 
proteins is that almost all induce an antibody response [169]. ADAs constitute a 
theoretical risk because they may lead to a loss of efficacy, altered pharmacokinetics, and 
potentially cause immunotoxicity [152, 153, 170, 171]. As CTB-KDEL is a derivative of 
the cholera vaccine antigen CTB, it is of critical importance to assess the consequences of 
an immune response to CTB-KDEL on its pharmacological and/or toxicological 
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parameters for its development as a drug for chronic diseases like UC, which would 
likely need repeated and long-term medication.  
 Typically, nonclinical models of immunogenicity are not always predictive of 
immune responses in humans [171]. However, in most cases, the studies are performed to 
identify the possibility of ADA induction and determine the capacity of ADAs, if elicited, 
to affect the pharmacokinetics and pharmacodynamics of the drug. It is already known 
that CTB is immunogenic in humans as well as in rodents [107]. Hence, we used multiple 
strains of mice to reveal the dynamics of CTB-KDEL’s immunogenicity on its 
therapeutic effects in colitis. To that extent, the study using C57BL/6 mice represented a 
scenario of high ADA induction, while C3H/HeJ mice provided a scenario of minimal 
ADA induction. Both scenarios were deemed important for the implications of CTB-
KDELs intestinal therapeutic effect. Nevertheless, CTB-KDEL was efficacious in both 
species of mice indicating the consequences of immunogenicity on its ability to treat UC 
are negligible.  
 
In the acute DSS colitis experiment in which C57BL/6 mice were pre-dosed twice 
with CTB-KDEL (i.e., “vaccinated”), we indeed observed significant levels of anti-CTB-
KDEL IgA antibodies in the intestine before DSS exposure and throughout the rest of the 
study (Figure 15D). Although we did not directly analyze the capacity of the ADAs to 
neutralize CTB-KDEL’s effect, the therapeutic efficacy observed in 
Vaccinated+Therapeutic+DSS group was not inferior to that of Therapeutic+DSS group, 
suggesting that intestinal ADAs arising from repeated CTB-KDEL administrations have 
limited impacts, if any, on the protein’s mucosal healing efficacy. However, 
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interpretation of the results from this experiment is complicated by the fact that the CTB-
KDEL vaccination also showed marked prophylactic effects against DSS colitis. Our 
preliminary study show that CTB-KDEL is only detectable in the colon up to 48 hours 
after a single oral administration in CTB-KDEL naïve mice (data not shown). Thus, the 
prophylactic effect of CTB-KDEL seen in Figure 15 could be due to the ADAs 
extending the bioavailability of the protein in the colon. Alternatively, the induction of 
ADAs itself might have played a beneficial role in mitigating inflammation because IgA 
is known to help maintain mucosal homeostasis and/or mediate anti-inflammatory 
functions [73, 74, 172-174]. In fact, this was previously demonstrated in CTB’s IgA-
dependent reduction of experimental asthma [75]. However, in this present study, the 
beneficial effects of CTB-KDEL wound not be due to the induction of IgA as 
demonstrated in the DSS-colitis model using C3H/HeJ mice Figure 16. C3H/HeJ mice 
have an intact adaptive immune system, however, lack the proper MHC II haplotype to 
bind CTB and consequently CTB-KDEL [158]. It has previously been determined that 
CTB peptide 89-100 is the major T cell epitope of CTB and that T cell recognition of 
CTB is dependent on the MHC II context of the host T cells. Therefore, C3H/HeJ mice 
do not produce ADAs or IgA when exposed to CTB or CTB-KDEL (Figure 6). Thus, 
how predosing of CTB-KDEL was just as effective as one therapeutic dose immediately 
after DSS exposure remains unknown.  
While we know CTB-KDEL induces epithelial restitution in the colon and this is 
the major contributing function of the proteins therapeutic effect, we cannot discount the 
role of the immune system in CTB-KDEL’s prophylactic effects. It has been 
demonstrated previously that CTB can have direct effects on immune system through the 
binding of GM1 ganglioside on immune cells which results in a immunosuppression [81, 
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107], such as Rouqeute-Jazdeanian et al. who showed that the binding of CTB directly to 
GM1 ganglioside prevented CD4+ T cells activation and proliferation. Additionally, 
others have shown that non-GM1 binding CTB mutants do not modulate immune 
function [79]. In support of these results, Coccia et al. determined that daily oral 
administration of 100 µg CTB over a four-day period inhibited mucosal Th1 cell 
signaling and Th1 cytokine production that resulted in the mitigation of 2,4,6-
trinitrobenzene sulfonic acid (TNBS)-induced mouse model of Crohn’s disease [77]. 
These findings were corroborated in a in a small multicenter, open-label, and 
nonrandomized clinical trial in patients with active CD, where 7 out 12 patients 
responded to six 5 mg oral doses of CTB treatment [78] Furthermore, D’Ambrosia et al 
demonstrated CTB promotes Treg cells by preventing monocyte-derived DC maturation 
[80] We have also shown that two weeks after two vaccinations with 30 µg of CTB-
KDEL, as performed in figures 4-6, increased Treg cells in the lamina propria while also 
reducing DSS-induced injury [50]. These effects may not necessarily be a direct effect of 
CTB-KDEL on immune cells but rather an indirect effect from IECs. Nonetheless, a 
similar phenomenon has also been reported by others, like Zang et al, who has shown 
intraperitoneal administration of CTB to rats increased Treg cells in the peripheral blood 
24–72 h after ischemia and decreased neurological dysfunctions and mortality rate [16, 
54-58]. Resident Treg cells are known inducers of tissue homeostasis and wound repair, 
functions that could significantly impact disease parameters in DSS-colitis [175]. It 
remains to be determined if CTB-KDEL’s prophylactic effect is mediated by immune 
cells or indirectly through IECs remains. Meanwhile, mice vaccinated with CTB-KDEL 
were greatly protected from DSS induced injury in C57BL/6 and C3H/HeJ mice unlike 
Rag1-/- mice (lacking both T and B cells [159]), where CTB-KDEL demonstrated a 
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relatively mild effect [159] (Figure 17). These data suggest an alternative function of 
CTB-KDEL in the colon mucosa, perhaps related to the adaptive immune system.  
Nonetheless, how CTB-KDEL’s effect persists two weeks after administration remains 
unknown. Future studies will need to address the impact of CTB-KDEL (and CTB) on 
the gut immune system of C3H/HeJ mice to uncover any alternative immunomodulatory 
functions of the molecule. 
In conclusion, the present study provides evidence for CTB-KDEL’s ability to 
treat chronic colitis. Additionally, we argue that immunogenicity is not a major risk for 
the mucosal healing activity of orally administered CTB-KDEL. Further research is 
needed to determine why ADAs did not neutralize or prevent CTB-KDEL’s activity and 
to determine whether this phenomenon is unique to CTB-KDEL or applies to other GI-
targeted biologics. Nevertheless, collectively these results support the development of 
CTB-KDEL for UC therapy. 
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CHAPTER 5: CTB-KDEL INDUCES A WOUND HEALING RESPONSE IN HUMAN 
IBD COLON TISSUES5 
 
 
5.1 Introduction 
As discussed in Chapter 1, CTB-KDEL is a plant-produced recombinant protein 
derived from cholera toxin B subunit (CTB) [89]. CTB is a non-toxic, pentameric, 
ganglioside GM1-binding subunit of cholera holotoxin. Recombinantly produced CTB is 
currently used as an active component in the internationally licensed oral cholera vaccine 
Dukoral® [106]. Additionally, CTB was shown to exhibit anti-inflammatory activities 
under various immunopathological conditions [69, 107]. For example, the airway 
administration of CTB ameliorated inflammation in an experimental asthma mouse 
model [75]. In a Phase I/II clinical trial, oral administration of CTB, chemically cross-
linked to a peptide from the human 60kDa heat shock protein, alleviated uveitis of 
Behcet’s disease [49]. Furthermore, oral administration of CTB blunted the intestinal 
inflammation of CD in a mouse model [77]. In a Phase I clinical trial, approximately 40% 
of patients with mild to moderate CD, who received thrice weekly oral administrations of 
5 mg of CTB for 2 weeks, showed significantly reduced disease activity indices [78]. 
These multiple lines of preclinical and clinical in vivo evidence, coupled with the history 
 
5 Modified from: FASEB J. 2019 Sep 27:fj201901255R. doi: 10.1096/fj.201901255R. 
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of use as an oral cholera vaccine, strongly highlight the potential of CTB and its 
derivatives as topical biotherapeutics.  As mentioned in Chapter 3,  the unique active 
CTB-KDEL in the aforementioned studies are unique to the plant-made variant, as it has 
a mutation at amino acid position 4 and an ER retention signal sequence at the C-
terminus (N4S-CTB-SEKDEL; [89]). The ER-retention sequence was added to CTB-
KDEL to improve production in planta, while Asn4→Ser mutation was introduced to 
avoid N-glycosylation [42, 89]. The addition of the KDEL sequence to N4S-CTB 
significantly reduced ER stress that otherwise caused poor production yield. This 
modification was critical to achieve high-level accumulation in leaf tissue [41, 42]. 
Despite the modification, the plant-made CTB variant, CTB-KDEL, is virtually identical 
to CTB in regard to GM1-binding affinity, molecular stability and vaccine efficacy to 
induce anti-toxin IgG and IgA antibodies upon oral immunization in mice [89]. The 
protein ER retention mechanism involving the KDEL receptor is highly conserved among 
eukaryotic organisms [102]. Chapter 3 revealed, CTB-KDEL exhibits unique colon 
mucosal would healing effects that are mediated by its localization in the ER via KDELR 
and subsequent activation of a UPR and TGFβ signaling in colon epithelial cells. 
Despite the striking finding described in chapters 3 and 4 the data presented were 
derived from immortalized cell culture systems and/or mouse models of colitis. The 
usefulness of nonclinical models is constantly questioned because of the homologous 
controlled conditions and poor recapitulation of human conditions [176]. Thus, it is 
imperative to evaluate CTB-KDEL’s efficacy in a more clinically relevant model to 
support its use for IBD therapy. Thus, here we investigated CTB-KDEL’s effect on 
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inflammation and tissue repair responses in colectomy tissue samples obtained from IBD 
patients.  
  
86 
 
 
5.2 Results 
To reveal if the UPR-mediated epithelial cell migration effects in Caco2 cells and 
epithelial recover activity in mice of CTB-KDEL could translate into a therapeutic effect 
in human colon tissues ex vivo. A sigmoid colon tissue of a 57-year-old male ulcerative 
colitis (UC) patient who underwent total colectomy was sectioned into 9 pieces, which 
were cultured with PBS, CTB-KDEL or CTB (n=3 for each treatment) for 24 h, and then 
UPR, TGFβ and wound healing signaling were analyzed by pathway-focused RT-qPCR 
arrays. Consistent with results observed in Caco2 cells (Figure 6), CTB-KDEL-treated 
tissue showed a significant upregulation of the IRE1 gene ERN1, PERK gene EIF2AK3 
and TGFB1, while there was no significant difference between PBS- and CTB-treated 
tissues (Figure 18A). Additionally, CTB-KDEL significantly upregulated 21 out of 84 
wound healing-related genes in the RT-qPCR array by >2 fold compared to PBS, while 
CTB significantly enhanced only 1 gene (MAPK1; Figure 18B). Of note, one of the 21 
genes significantly increased by CTB-KDEL was the E-cadherin gene CDH1, which was 
also upregulated in the acute DSS model (Figure 10B). Congruent with the RT-qPCR 
results, histopathological analysis showed that CTB-KDEL-treated tissues (n=3) had 
early stage crypt formations and relatively low neutrophil infiltration in the mucosa, 
while PBS- and CTB-treated tissues did not have such distinct histological features 
(Figure 19C). Since CTB-KDEL-treated tissue was cut adjacent from PBS or CTB-
treated ones, these observations likely reflect the effects of treatment.   
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Figure 18. Effects of CTB-KDEL and CTB in human colon tissue isolated from a 57-
year-old male UC patient who underwent colectomy. CTB-KDEL induces UPR, 
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TGFβ and wound healing signaling in human colon colectomy tissue. The sigmoid colon 
tissue was divided into nine adjacent sections and cultured with PBS, or 1 µM of CTB-
KDEL or CTB for 24 h. (A) RT-qPCR analysis of UPR and wound healing gene 
expression. One-way ANOVA with Bonferroni’s multiple comparison tests was used to 
compare all pairs of groups. Mean ± S.D. is shown for each group (N = 3). (B) Wound 
healing pathway-focused qRT-PCR analysis of gene expression in human UC patient 
colectomy tissue. Volcano plots show P value (y axis) and fold-change (x axis) for all 84 
genes in the wound healing pathway upon treatment with PBS vs. CTB-KDEL (left) and 
PBS vs. CTB (right). Dots represent ≥ 2-fold upregulation (red), ≥ 2-fold down-
regulation (green), or < 2-fold change (black). The area corresponds to > 2-fold increase 
with P values < 0.05 is highlighted with a red box. Values were calculated by the data 
analysis web portal at http://www.qiagen.com/geneglobe (N = 3 per treatment). (C) 
Human UC patient colectomy tissue H&E stain. Representative 4x (left) and 10x (right) 
photomicrographs of H&E stained sigmoid colon tissues from each group. Arrows point 
to crypt formations. 
 
CTB-KDEL’s wound healing effects were further validated in additional IBD 
colon tissues. Altogether, colectomy tissues from 5 patients were treated with CTB-
KDEL or vehicle control (PBS) ranging from 20 to 72 years old, including two Crohn’s 
Disease patients (a 57-year-old male and a 60-year-old female). Albeit to varying 
degrees, CTB-KDEL significantly upregulated multiple wound healing-associated genes 
by over two-fold in all 5 patients’ tissues (Figure 19A). In contrast, there was no gene in 
the wound healing pathway analyzed that was significantly downregulated by CTB-
KDEL in any of the tissues (data not shown). The most notable effect was observed in a 
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sigmoid colon tissue from a 20-year-old male UC patient, in which CTB-KDEL 
significantly enhanced as many as 79 out of 84 wound healing-associated genes analyzed 
(Figure 19A). As observed in the mouse DSS model (Figure 10B), CTB-KDEL 
significantly increased CDH1, TGFB1 and WNT5A (Figure 19B). The robust 
upregulation of wound healing genes was accompanied with distinct crypt formations and 
relatively low neutrophil infiltration in the mucosa of CTB-KDEL-treated tissues in 
contrast to those treated with PBS. Ki67 IHC analysis corroborated the histopathological 
observation, which depicts live, proliferating crypt formation in CTB-KDEL treat tissues 
(n=3) (Figure 19C). Taken together, the above results provide evidence that CTB-KDEL 
can exhibit wound healing activity in human IBD colon tissues, highlighting the protein’s 
therapeutic potential.   
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Figure 19. Effects of CTB-KDEL and CTB in human colon tissue from IBD patients 
who underwent colectomy. (A) Wound healing pathway-focused qRT-PCR analysis of 
the number of genes upregulated in treated human UC or Crohn’s disease (CD) patient 
colectomy tissues by CTB-KDEL compared to the PBS vehicle control. The graph shows 
number of gene ≥ 2-fold upregulated. Values were calculated by the data analysis web 
portal at http://www.qiagen.com/geneglobe (N = 3/patient). (B) RT-qPCR analysis of 
TGFB1, CDH1 and WNT5A gene expression 24 h after treatment in the tissue from the 
20-year-old (20yo) male UC patient. Mean ± S.D. is shown for each treatment (N = 3). 
Two-tailed unpaired t-test was used to compare groups. **, ***P < 0.01, 0.001. (C) 
Representative 4x (left) and 10x (right) H&E-stained and Ki67 immunohistochemistry 
photomicrographs of the 20yo male UC patient colectomy tissue.  
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5.3 Discussion 
The data generated from the murine models of DSS colitis presented in Chapters 
3 and 4 strongly support the notion that oral administration of CTB-KDEL can facilitate 
colon epithelial restitution and wound healing, at least in the conditions tested. In 
corroboration of the acute and chronic DSS models, here we demonstrated the mucosal 
healing potential of CTB-KDEL in an explant culture model using human IBD patient 
colectomy tissues (Figure 18 and Figure 19). Although the number of patient colon 
tissues tested in this study is limited, all five patient specimens showed upregulation of 
wound healing-related genes in response to CTB-KDEL treatment, in contrast to PBS or 
CTB. Of note is that, consistent with the findings in the DSS model, CTB-KDEL 
significantly activated UPR, TGFβ signaling pathways, CDH1 and WNT5a (Figure 18). 
Additionally, new crypt formations were observed in CTB-KDEL-treated tissues (Figure 
18 and Figure 19). We acknowledge, however, that the wound healing response induced 
by CTB-KDEL substantially varied among the different patients’ tissues tested, for which 
the underlying mechanism remains unknown. The least wound healing response was 
observed with the 72-year-old male UC patient, which may be explained by an age effect; 
recently, it has been reported that aging individuals experience delayed and impaired 
healing of the gastric mucosa due to reduced angiogenic capacity [177]. Nonetheless, 
these results overall support the premise that CTB-KDEL could induce mucosal healing 
in IBD patients, warranting a further study using additional tissue specimens. As there is 
no cure available for IBD, mucosal healing is currently regarded as the standard treatment 
goal in IBD therapy [4, 6-8]. Current therapeutic options can indirectly achieve mucosal 
healing in only ~50% of patients and their direct effect on epithelial repair remains 
elusive [15, 16, 178]. Thus, the results presented herein provide implications for the 
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unique therapeutic potential of CTB-KDEL that may address a significant unmet need in 
UC treatment. 
In conclusion, the data herein reveal that the mechanism of action of CTB-KDEL 
demonstrated in nonclinical studies also induces mucosal wound healing pathways and 
observable histological improvements in the colectomy tissues of IBD patients treated ex 
vivo.  These data provide the proof of concept of CTB-KDEL’s remarkable efficacy and 
provide justification for its use in a first-in-human Phase I trial to support its development 
as a new agent for the treatment of inflammatory bowel disease.   
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CHAPTER 6:  SUMMARY AND IMPLICATIONS FOR FUTURE DIRECTIONS 
 
 
6.1 Summary 
Although there is currently no curative therapy available for UC, the recent 
advent of anti-TNFα agents has revealed that mucosal healing provides an important 
clinical endpoint in UC treatment, as it is closely associated with sustained clinical 
remission, improved quality of life and fewer surgical operations and cancer incidence 
[4-9]. The development of new drug candidates for mucosal healing represent a 
significant unmet need in UC management. However, currently there is no mucosal 
wound repair product indicated for UC available or in clinical trials (ClinicalTrials.gov, 
as of August 28, 2019).  Previously, we have proposed that a modified CTB containing 
an artificial ER retention motif (CTB-KDEL) could be used to facilitate mucosal healing 
in the management of UC. Here, we determined the mechanisms by which CTB-KDEL 
induces colon epithelial mucosal healing.  This effect was revealed in a series of 
experiments where we first determined in a Caco2 cell wound-healing model that variants 
of CTB-KDEL that lack the terminal KDEL sequence (CTB and CTB-KDE) failed to 
induce cell migration in Caco2 cells Figure 2. It was further determined that CTB-KDEL 
colocalized with KDELR and remained longer than CTB within the ER of Caco2 cells 
(Figure 4 and Figure 5). This prolonged retention of CTB-KDEL increased the levels of 
UPR sensors by 1.5 – 2-fold in Caco2 and mouse primary colon epithelial cells, as well 
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as in a human UC colon tissue (Figure 6, Figure 8, and Figure 18) Subsequently, 
genetic and chemical inhibition of IRE1-XBP1 signaling completely abolished the TGFβ 
upregulation and cell migration effects of CTB-KDEL in Caco2 cells (Figure 7). 
Combined with our previous data showing that GM1 binding is essential for CTB-
KDEL’s wound healing effect in Caco2 cells [50], these data strongly suggest that the C-
terminal KDEL sequence rendered CTB-KDEL with a unique new wound healing 
activity in the colon epithelial cells via localization to the ER, UPR activation and 
subsequent TGFβ signaling.  
CTB-KDEL’s capacity to induce a UPR and epithelial restitution/wound healing 
was corroborated in a DSS-induced acute colitis mouse model where a single oral 
administration of as little as 3 µg of CTB-KDEL significantly enhanced recovery from 
colitis (Figure 9 and Figure 10). The therapeutic effects were characterized by enhanced 
epithelial regeneration, demonstrated by E-cadherin IHC and upregulated Cdh1 and 
Wnt5a levels, suggesting that the rapid resolution of epithelial injury is the primary 
mechanism of CTB-KDEL’s efficacy in this model Figure 10. Due to the fact that acute 
DSS-induced colitis typically only incorporates features of innate immunity and acute 
epithelial injury, Chapter 4 addressed the therapeutic potential of CTB-KDEL in a 
chronic progressive model of colitis. We implemented an established model of chronic 
colitis (Figure 11) by giving repeated DSS exposures to mice that is known to create a 
complex interplay between innate immune responses and compromised epithelial barrier 
function that drives a chronic sustained inflammatory response [96, 149, 150]. 
Subsequently, we found that weekly oral administration of CTB-KDEL dosed before or 
after the onset of chronic conditions induced by repeated DSS exposure, could 
significantly reduce DAI scores, intestinal permeability and pro-inflammatory cytokines 
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(Figure 12). The therapeutic efficacy of CTB-KDEL against chronic colitis was 
corroborated by histological evidence for significant remission and healing in CTB-
KDEL treated mice. In addition, it was also noted that there was minimal neutrophil 
infiltration in tissues of CTB-KDEL treated mice in contrast to vehicle control (Figure 
13). The data also revealed that QWd7 and Q3Dd35 dosing of CTB-KDEL were more 
efficacious than QWd35 dosing (Figure 12). This provides a basis for both QW and 
Q3Dd35 dosing to be used in the treatment of chronic colitis; QW dosing may be 
sufficient as a maintenance dose to prevent relapse of disease, while Q3Dd35 dosing may 
be better suited for treatment of active disease. 
Moreover, we have previously shown that oral administrations of 3, 10, or 30 µg 
CTB-KDEL twice at a two-week interval induced anti-CTB-KDEL neutralizing 
antibodies [89]. However, Figure 12 and Figure 13 demonstrate that CTB-KDEL did not 
lose its efficacy with repeated dosing (8 doses total QWd7). A key pharmacology and 
toxicology question for biotherapeutic development is immunogenicity; specifically, 
ADAs. A major disadvantage of therapeutic proteins is that almost all induce an antibody 
response [169]. ADAs constitute a theoretical risk because they may lead to a loss of 
efficacy, altered pharmacokinetics (PK), and potentially cause immunotoxicity [152, 153, 
170, 171].  Thus, to address the consequences of immunogenicity, mice (C57BL/6, C3H, 
or Rag1-/- strains) were pre-exposed to CTB-KDEL, and then subjected to DSS colitis 
and CTB-KDEL treatment (Figure 14). While the pre-dosing of CTB-KDEL indeed 
elicited high-titer anti-drug antibodies (ADAs) of the IgA isotype in the intestine of 
C57BL/6 mice, the therapeutic effects of CTB-KDEL were similar and better than those 
observed in C3H and Rag1-/- mice, respectively, both of which showed few ADAs under 
the same experimental conditions (Figure 15, Figure 16, and Figure 17). Thus, the 
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immunogenicity of CTB-KDEL does not seem to impede the protein’s mucosal healing 
efficacy. These data argue that immunogenicity is not a major risk for the mucosal 
healing activity of orally administered CTB-KDEL. However, further research is needed 
to determine why ADAs do not neutralize or prevent CTB-KDEL’s activity and to 
determine if this phenomenon is unique to CTB-KDEL or applies to other GI-targeted 
biologics. 
Lastly, to address if CTB-KDEL could induce mucosal healing in IBD patients, 
we determined the mucosal healing potential of CTB-KDEL in an explant culture model 
using human IBD patient colectomy tissues. In these studies, CTB-KDEL induced an 
UPR, upregulated wound healing pathways and maintained viable crypts in colon 
explants from IBD patients (Figure 18 and Figure 19). These data revealed that the 
mechanism of action of CTB-KDEL demonstrated in nonclinical studies also induces 
mucosal wound healing pathways in the colectomy tissues of IBD patients treated ex 
vivo.  These data provide the proof of concept of CTB-KDEL’s efficacy and provide 
justification for its use in a first-in-human Phase I trial to support its development as a 
new agent for the treatment of IBD.   
 
6.2 Future Directions 
Herein our in vivo and ex vivo studies revealed how CTB-KDEL elicits its unique 
therapeutic effects in colitis. [36-39, 51, 52] It was determined that there are at least three 
necessary components of CTB-KDEL’s mechanism of action (MOA) that are essential 
for CTB-KDEL’s TGFβ-mediated would healing effect [50]. First, endocytosis into cells 
via GM1 ganglioside binding; second, induction of an UPR mediated by the prolonged 
retention of CTB-KDEL in the ER by the KDELR; and lastly, induction of TGFβ 
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mediated by IRE1/XBP1 signaling.  While we have identified these three essential 
checkpoints in CTB-KDEL’s MOA, there remains unanswered questions around each 
molecular phenomenon. 
 First, CTB-KDEL MOA is initiated by the binding of GM1 ganglioside that 
allows CTB-KDEL to be endocytosed into the cell. While this is not the only route of 
CTB into cells, we have proved it is essential for CTB-KDEL’s therapeutic effect 
(Figure 20). One might speculate that other KDEL tagged proteins could also induce a 
similar effect. However, the data presented in Figure 20 and Figure 21 suggest that GM1 
may critical roles in epithelial repair induced by CTB-KDEL (discussed below).   
CTB is known to bind to glucosylated proteins, with a superior affinity for the 
branched pentasaccharide moiety of ganglioside GM1 [179]. Previous studies have 
shown that CTB can bind more than just GM1 as demonstrated by fluorescence-activated 
cell sorting of mouse embryonic neuroepithelial cells treated with CTB that revealed 
CTB binding did not coincide with GM1 expression levels, suggesting alternative 
receptors are present [180].  Alternative receptors with affinity for CTB, although much 
lower than GM1, have been identified, many of which are GM1 ganglioside-like 
receptors such as GM2 and GD1a or glycoprotein type receptors [37, 38, 181, 182].  In line 
with these findings we found that CTB-KDEL and the non-GM1 binding G33D-CTB-
KDEL (Figure 20) both bind to Caco2-cells, albeit G33D-CTB-KDEL’s binding to 
Caco-2-cells was much weaker than CTB-KDEL’s,  and co-localized with the KDELR in 
Caco2-cells (Figure 21). However, only CTB-KDEL induced an UPR, increased TGFβ 
levels, and subsequent wound healing (Figure 6, Figure 8, & Figure 20). These data 
suggest that GM1-ganslioside plays more of a role in CTB-KDEL MOA other than just 
cell entry.  We speculate that the cell-surface GM1-ganglioside that is brought to the ER 
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as a complex with CTB-KDEL may be primarily responsible for UPR activation. 
Previously, Tessitore et al demonstrated that accumulation of GM1-ganglioside in the ER 
resulted in an UPR that was characterized by an upregulation of ER chaperones, such as 
BiP, and XBP1 activation [183]. These effects were attributed to GM1-induced calcium 
depletion in the ER because of a reduction in the sarcoplasmic/ER calcium ATPase 
activity, which is responsible for calcium uptake into the ER [184]. These results were 
later corroborated by Sano et al. who revealed that GM1-ganglioside accumulates in a 
glycosphingolipid-enriched microdomain of the mitochondria-associated ER membranes 
[185].   In these studies, excess GM1-accumulation in the ER was shown to induce 
Ca2+ flux from the ER to mitochondria and a UPR, which resulted in ER stress- and 
mitochondria-mediated apoptosis of neuronal cells.  However, CTB-KDEL may not 
cause such excess accumulation of the ganglioside in the ER and a cytotoxic UPR 
response, as we did not observe any cytotoxic response to CTB-KDEL in Caco2 cells 
(Figure 2). In our preliminary study using polarized T84 cell monolayers, we found that 
the levels of UPR marker genes induced by CTB-KDEL were significantly lower than the 
well-known UPR inducer thapsigargin (data not shown). We postulate that the amount of 
cell-surface GM1 ganglioside sequested by CTB-KDEL was a limiting factor. 
Alternatively, the availability of KDELR was limited, whereby the receptor became 
saturated before the concentration of CTB-KDEL reached a point that overload GM1 in 
the ER.  
Meanwhile, the data in Figure 6 showed that CTB-KDEL can directly interact 
with BiP. Therefore, a question remains whether the accumulation of GM1 (via complex 
with CTB-KDEL) in the ER is sufficient to induce IRE1-XBP1 signaling or the binding 
of CTB-KDEL to BiP also plays a role in the initiation of UPR. Additionally, it remains 
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to be determined if CTB-KDEL also directly interacts with IRE1 to displace BiP since 
IRE1 signaling can be activated by the binding of proteins (unfolded) to its peptide 
binding groove after the release of BiP [186-189]. Future research should determine the 
relative contributions of GM1 and CTB-KDEL to epithelial repair activity and how 
exactly the UPR is activated for subsequent TGFβ upregulation.  
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Figure 20. Characterization of G33D-CTB-KDEL. Nucleotide G at position 161 was 
mutated to an A (for Gly33 to Asp CTBp), creating pNM175.  G33D-CTB-KDEL was 
expressed and purified as previously described (10).  (a) SDS PAGE analysis.  10 ug of 
purified CTB-KDEL (lane 2) and G33D-CTB-KDEL (lane 1) appeared as monomers 
under heat denaturing conditions. (b) SF-HPLC analysis. Chromatography was 
performed on a Beckman Coulter System Gold HPLC.  CTBp or G33D-CTB-KDEL was 
applied to an SEC column and elution was monitored by absorbance at 280 nm. The large 
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peak corresponds to pentamers of CTB purified to >95% homogeneity; the minor peak is 
likely decameric [Yasuda et al. 1998]. (c) GM1 ganglioside ELISA was performed as 
previously described [10]. G33D-CTBp showed no affinity towards GM1 ganglioside, 
samples were ran in duplicate and analyzed by GraphPad Prism 5.0. (d) CTB sandwich 
ELISA where CTBp and G33D-CTBp were captured by rat anti-CTB mAb and detected 
by goat anti-CTB.  No significant difference was observed between either CTB protein in 
the binding affinities of anti-CTB antibodies, samples were run in duplicate and analyzed 
by GraphPad Prism 5.0.  (e) Wound Healing Assay.  Analysis of in vitro wound closure 
after 24 h by wound area measurement.  G33D-CTB-KDEL does not enhance wound 
healing.  Means ± SEM of four independent experiments are shown. *P < 0.05, **P < 
0.01, and ***P, 0.001; one-way ANOVA with Bonferroni’s multiple comparison tests. 
(Baldauf and Royal et al. Muco Imm 2017)  
 
The second essential component of CTB-KDEL’s MOA is the ability to bind to 
the KDELR. In a Caco2 cell wound-healing model, CTB-KDEL, but not CTB or CTB-
KDE, facilitated cell migration via interaction with the KDELR, localization in the ER, 
UPR activation and subsequent TGFβ signaling. Since native CTB lacking an ER 
retention motif also has the ability to complex with GM1 and traverse through the 
endomembrane system, it is clear that KDELR plays a critical role that allows CTB-
KDEL and/or GM1 to trigger an UPR in the ER for a subsequent epithelial repair 
response.  Inhibition of the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 
(XBP1) arm of UPR abolished the cell migration effect of CTB-KDEL, indicating that 
the pathway is indispensable for the activity. Here the question remains how CTB-KDEL 
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induces IRE1/XBP1 pathway.  The data in Figure 6 suggests that the binding of CTB-
KDEL to BiP plays a role in the initiation of UPR seen with CTB-KDEL treatment.  
What is unknown is if CTB-KDEL also directly interacts with IRE1 to displace BiP or if 
the binding of the KDELR alone is sufficient to induce BiP dissociated from IRE1 and 
subsequent downstream signaling.  There is also a possibility that the UPR response is in 
part attributed to competition between CTB-KDEL and BiP for KDELR, as BiP relies on 
KDELR for retrieval back to the ER [121, 190-192].  In this regard, the role of KDELR 
in CTB-KDEL-induced epithelial repair activity warrants further investigation. 
 
 
Figure 21. G33D-CTB-KDEL loosely binds to Caco2 cells and localizes with the 
KDEL receptor (KDELR).  Flow cytometry analysis of Caco2 cells incubated with 
CTB-KDEL, CTB, or G33D-CTB-KDEL at room temperature (A) or (B) on ice. (A) 
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Caco2 cells were treated with 1µM CTB-KDEL, CTB, or G33D-CTB-KDEL  at room 
temperature for 15 minutes then fixed and stained with anti-CTB labeled Alexa Fluor 488 
antibody then analyzed by Flow cytometry (n= 4). (B) Caco2 cells were treated with 1µM 
CTB-KDEL, CTB, or G33D-CTB-KDEL  on ice for 15 minutes then fixed and stained 
with anti-CTB labeled Alexa Fluor 488 antibody then analyzed by Flow cytometry (n = 
4).  (C) Immunofluorescence analysis of G33D-CTB-KDEL intracellular localization 
within the ER. Caco2 Cells were treated with 1 µM of G33D- CTB-KDEL, or a vehicle 
control (PBS) for 24 h. Cells were fixed/permeabilized and stained with an anti-CTB 
monoclonal antibody detected by Alexa FluorTM 488 (green), Anti-KDEL polyclonal 
antibodies (red), and DAPI (blue). See Figure 5 for vehicle control, CTB, and CTB-
KDEL corresponding data.  
The third essential component of CTB-KDEL’s MOA is the induction of TGFβ. 
CTB-KDEL’s epithelial repair activity seems to be mediated by TGFβ, as an anti-TGFβ 
antibody and  small molecule inhibitor of TGFβ intracellular signaling (SB-431542 
[193]; data not shown) completely inhibited the CTB-KDEL’s cell migration effect in 
Caco2 cells [50].  CTB-KDEL’s ability to regulate TGFβ is mediated through 
IRE1/XBP1 signaling, as demonstrated in Figure 7. However, how IRE1/XBP1 signaling 
leads to TGFβ upregulation is still unknown. This phenomenon has been studied by 
Chusri et al. in the context of increased TGFβ levels in hepatitis C virus (HCV) infected 
hepatocytes [132].  The authors demonstrated that all three arms of the UPR were 
activated in HCV-infected liver cells, which was responsible for the increased TGFβ 
levels. Interestingly, it was determined that HCV infection led to NFκB activation 
through the IRE1/XBP1 pathway and that inhibition of this pathway reduced HCV-
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induced TGFβ elevation.  Thus, it is possible that CTB-KDEL also activates NFκB 
following UPR stimulation. However, NFκB regulates numerous cellular pathways as 
well as the expression of a variety of proteins besides TGFβ that inhibit apoptosis, 
regulate the immune system, promote cell survival/proliferation. Additionally, NFκB is 
implicated in carcinogenesis [194, 195]. NFκB signaling can be broken down into two 
pathways, canonical and non-canonical. The canonical NFκB pathway is associated with 
cell survival responses, cellular proliferation, and/or inflammatory signaling, while the 
non-canonical pathway leads to lymphoid organogenesis, and the production of 
chemokines and cytokines. Both pathways have distinct nuclear factors that are activated 
during signaling, such as IκBα for the canonical pathway, while the non-canonical 
pathway activates the RelB/p52 NF-κB complex that relies on the processing of p100 
instead of degradation of IκBα [196].  Thus, a stepwise approach to first determining 
which NFκB pathway is activated by CTB-KDEL may prove to be insightful in 
determining how or if the protein utilizes the transcription factor.  
While determining how CTB-KDEL enhances TGFβ levels may help identify a 
new drug target, it is also of high priority to investigate the consequences of TGFβ 
activation on the GI tract.  TGFβ is a pleiotropic cytokine playing critical roles in cell 
differentiation and proliferation, as well as dynamic biological processes in wound 
healing and immune responses [23, 197, 198]. The cytokine is also involved in various 
pathological conditions. For example, elevated TGFβ levels have been correlated to the 
development of fibrosis following injury to the skin [199]. TGFβ mediates epithelial-to-
mesenchymal transition (EMT) [200], and reduction of TGFβ1 levels in a mouse model of 
pulmonary fibrosis blunted fibrosis [201]. TGFβ signaling also has important implications 
in cancer. Although the cytokine functions as a suppressor of tumorigenesis at an early 
106 
 
stage of tumor development, its expression is correlated with tumor progression and poor 
prognosis at late stages [23, 202]. Collectively, the two-sided nature of TGFβ points to the 
importance of careful investigation of possible consequences upon long-term CTB dosing 
for the treatment of chronic inflammatory diseases. As mentioned in the Introduction 
section, CTB-KDEL treatment significantly mitigated gut inflammation and reduced 
tumor development in a model of CAC [50], providing a basis for further investigations 
of the effects of long-term therapeutic use of CTB-KDEL for the treatment of IBD. 
As discussed above, we have discovered that CTB-KDEL utilizes a unique 
mechanism to induce increased epithelial cell TGFβ signaling and subsequent migration 
towards wound healing. However, the potential impacts of CTB-KDEL on other cell 
types remain largely unknown. GM1 ganglioside is broadly found on various cell types 
such as epithelial cells, macrophages, dendritic cells (DCs), B cells, T cells, and neurons 
[36-39]. But outside of what have been presented in this dissertation, the research of the 
effects of CTB or CTB-KDEL on different cell type has focused on the presence of GM1 
ganglioside on the luminal surface of APCs. This is due to CTB’s strong mucosal 
immunostimulatory effects associated with MHC class II expression and local antigen 
enrichment [40]. For instance, in a mouse model of asthma, CTB suppressed the ability 
of DCs to prime for Th2 responses to an inhaled allergen and caused a TGFβ-dependent 
increase in antigen-specific IgA in the airway luminal secretion. The induction of IgA 
appeared to be essential as CTB’s therapeutic effects were abrogated in mice lacking 
luminal IgA transporter (polymeric Ig receptor) [75]. In a 4, 6-trinitrobenzenesulfonic 
acid (TNBS)-induced acute colitis mouse model, CTB administration reduced IL-12 and 
IFNγ secretion, inhibited STAT-4 and STAT-1 activation and downregulated T-bet 
expression, indicating that CTB inhibited mucosal Th1 cell signaling [77]. In vitro, CTB 
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decreased monocyte-derived DC maturation and IL-12 production upon 
lipopolysaccharide (LPS) stimulation in vitro. Moreover, CTB-pretreated, LPS-
stimulated DCs induced low proliferating T cells that had enhanced production of IL-10 
and reduced production of IFNγ [80].  
It remains to be determined whether CTB-KDEL exhibits any immunomodulatory 
effect on immune cells like CTB. We do know, however, vaccination with CTB-KDEL 
(as shown in Figure 14) significantly increased Th2, Treg and Th17 cells and decreased 
B cells in the lamina propria [50] . Thus, there is evidence suggesting that CTB-KDEL 
modulates B and T cells, although the consequences and underlying mechanism remain 
unknown. As shown in Chapter 4, CTB-KDEL showed both prophylactic and therapeutic 
effects against mitigated DSS colitis in C3H mice.  However, in this study, the effects 
would not be due to CTB-KDEL’s capability to stimulate a classic adaptive immune 
response since C3H mice lacks the proper MHC II haplotype to bind CTB and 
consequently CTB-KDEL [158]. In fact, we observed a very low, if any, anti-CTB IgA in 
these mice (Figure X). Since the prophylactic effect of CTB-KDEL was not seen in 
RAG1 KO mice, these data suggest an alternative function of CTB-KDEL in the colon 
mucosa, perhaps related to the direct binding of CTB-KDEL to GM1-ganglioside on 
adaptive immune cells. Future studies will need to address the impact of CTB-KDEL 
(and CTB) on the immune cells of C3H mice to uncover any alternative 
immunomodulatory functions of the molecule. 
Even though CTB first encounters IECs upon oral administration, the CTB-
mediated modulation of IECs and the consequence of IEC modulation on the mucosal 
immune system have largely been ignored in comparison to the protein’s direct impacts 
on immune cells. Previously, we have shown that CTB-KDEL alters the levels of 
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inflammatory and wound healing-related cytokines secreted by the colon epithelial cell-
line Caco2, hinting that CTB-KDEL could induce epithelial cell-mediated immune 
modulation [50]. Additionally, we have shown that oral administration of CTB-KDEL in 
mice had pronounced impacts on the distal GI tract, whereby TGFβ-mediated pathways 
were significantly activated in the colon mucosa along with increase in innate immune 
cell populations including DCs, natural killer (NK) cells and macrophages (both M1 and 
M2) in the colon lamina propria [50]. Given that there is a strong link between epithelial-
derived TGFβ and innate immune cells in wound healing [18, 92-94], future research 
should also address the impact of CTB-KDEL on the innate immune cells of the mucosa 
as well as different cell types lining the epithelium, such as crypt-base stem cells, goblet 
and endocrine cells and enterocytes [203], as GM1 is widely expressed on the surface of 
a wide variety of cell types.  
Chapters 3 and 4 addressed the ability of CTB-KDEL to mitigate acute colitis, 
prevent chronic colitis, and resolve chronic colitis symptoms. While CTB-KDEL was 
efficacious in all scenarios, additional models of IBD should be implemented to validate 
the therapeutic potential of this molecule. IBD is a heterogeneous disorder that 
encompasses various phenotypic subtypes and clinical appearances. There is no single 
animal model that incorporates all aspects of human IBD. Additionally, no two animal 
models of IBD are pathologically the same, but the multiple models of IBD together can 
replicate many of the aspects of human IBD subtypes. For example, when DSS is 
administered to mice, as used in Chapters 3 and 4, it causes a disruption of the intestinal 
epithelial barrier that allows the entry of luminal bacteria and bacterial antigens into the 
mucosa that results in an immune response [95]. The immune response leads to 
inflammation limited to the colon and subsequent colonic mucosal damage that is 
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characterized by ulcers/erosions, loss of crypts, and infiltration of granulocytes.  Many 
studies have performed DSS-colitis experiments using animals that have a variety of 
genetic deficiencies in permeability [204-206] and have revealed that some of these mice 
are more susceptible to DSS colitis. In line with these data, drugs that reduce gut 
permeability or maintain barrier integrity are protective against DSS-induced damage 
[160, 206, 207]. Therefore, since CTB-KDEL induces epithelial restitution and wound 
repair, it is compelling that the protein can effectively mitigate DSS-colitis, as presented 
in chapters 3 and 4. As shown in Chapter 4, Rag1-/- mice developed colitis when given 
DSS despite lacking T and B cells, indicating that the inflammation and damage were 
driven by the innate immune system [95]. Therefore, while DSS-induced colitis is a great 
model to assess gut integrity, mucosal responses to gut microflora and innate immune 
functions, it does not completely mimic human IBD, as vast epithelial cell damage and 
extensive invasion of the lamina propria by bacteria and bacterial antigens is unlikely to 
be a principal mechanism of human IBD [160]. Additionally, human IBD is characterized 
by polarized T cell responses, whereas the chronic inflammation induced by DSS 
exposure is characterized by a mixed Th1 and Th2 response [95, 149].   
Unlike DSS-induce colitis, the haptenating agent TNBS induces T cell mediated 
inflammation and subsequent intestinal damage. Intrarectal administration of TNBS 
results in hapteniztion of the colonic proteins and thereby initiates an mucosal Th1 cell-
mediated immune response and characterized by infiltration of the lamina propria with 
CD4+ T cells, neutrophils, and macrophages as well as development of severe diarrhea, 
weight loss, and rectal prolapse. [95, 149]. TNBS colitis has been widely used in the 
study of immunologic aspects relevant to Crohn’s disease, as many of the characteristics 
of TNBS colitis, including transmural inflammation and IL-12/INFγ cytokine secretion 
110 
 
patterns, resemble features of Crohn’s disease [95, 149, 160]. Interestingly, the TNBS 
colitis model has greatly contributed to our understanding of CTB’s ability to mitigate 
inflammation. Boirivant et al implement a TNBS-colitis model where daily oral 
administration of CTB after the onset of TNBS-colitis immediately resolved weight loss 
and reduced inflammation [70]. As discussed previously, CTB administration also 
reduced IL-12 and IFNγ secretion, inhibited STAT-4 and STAT-1 activation, and 
downregulated T-bet expression, indicating that CTB inhibited mucosal Th1 cell 
signaling [77]. It should be noted that CTB failed to prevent DSS-colitis in our study, 
which is in sharp contrast to the findings by Boirivant et al. Although a direct comparison 
to the therapeutic effects induced by CTB-KDEL cannot be made due to two different 
animals models of IBD, the discrepancy in CTB’s efficacies could be in part explained by 
the different dose amounts and timings employed in those two studies; whereas Boirivant 
et al. administered 4 daily doses of 100 µg CTB immediately after the administration of 
TNBS [70, 77], we dosed one 3 µg dose of CTB-KDEL or CTB at the end of DSS 
exposure. This points to the possibility that the low dose of CTB was not sufficient to 
show a therapeutic effect in the DSS model. Conversely, whether CTB-KDEL at high or 
low dose levels exhibits T cell-inhibitory effects like CTB remains to be determined.   
 In addition to adding to our understanding of CTB’s ability to mitigate 
inflammation, the TNBS-colitis model has also contributed to our understanding that 
intestinal inflammation can be abrogated by oral tolerance. Previously, is has been 
reported that oral administered haptenized colonic proteins (HCP) before rectal 
administration of TNBS effectively suppressed TNBS-induced colitis [208]. Of note, the 
suppression was shown to be due to the generation of mucosal Treg cells that produced 
TGFβ and a Th2 cells response. Additionally, CD4+ T cells isolated from the lamina 
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propria of HCP-fed animals had a 5 to 10-fold increase in their production of TGFβ. 
Concomitant systemic administration of anti-TGFβ diminished the protective effects seen 
in HCP-fed animals. Thus, the report was the first to show that TGFβ induction can help 
prevent and/or resolve experimental TNBS-colitis, even after disease was established. 
Furthermore, these data were also the first to implicate the regulation of TGFβ levels in 
the treatment of IBD [208]. It would be of great interest to test the ability of CTB-KDEL 
to mitigate TNBS-colitis in future research. As CTB-KDEL was shown to induce TGFβ 
signaling in the colon (Figure 18) and a wound healing response in colonic explants from 
Crohn’s disease patients (Figure 19), the TNBS model could further reveal the 
therapeutic potential of CTB-KDEL in Crohn’s disease. 
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6.3 Conclusion 
 
The data herein revealed that CTB-KDEL exhibits unique colon mucosal would 
healing effects, which are at least in part mediated by its localization to the ER and 
subsequent activation of IRE1-XBP1 signaling in colon epithelial cells. The studies 
presented herein strongly suggest CTB-KDEL’s potential as an effective mucosal healing 
agent with the potential to address an unmet need for the treatment of inflammatory 
disorders of the mucosa.  As current best medical treatment therapies, such as Anti-TNFα 
agents, have limited efficacy for the induction of mucosal healing [15, 16] and pose 
severe adverse reactions due to systemic administration [209-211]. In contrast, oral 
administration of CTB-KDEL might cause few, if any, systemic adverse effects and can 
directly heal lesions/ulcers and blunt inflammation. Therefore, CTB-KDEL provides a 
first-in-class therapeutic candidate for IBD that can effectively treat intestinal damage 
and induce mucosal healing without suppressing systemic immune functions, a 
significant unmet need in current IBD treatment. To aid in the development of CTB-
KDEL as a therapeutic agent, further research that delineates the detailed mechanisms by 
which CTB-KDEL induces mucosal healing is warranted.  
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